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Abstract 1: Melatonin has been reported to enhance the differentiation of
osteoblasts. The purpose of this study was to determine the melatonin treatment that
would differentiate human mesenchymal stem cells (hAMSCs) into osteoblasts. A 21
d continuous melatonin treatment significantly increased the alkaline phosphatase
(ALP) activity and the deposition of calcium in hAMSCs. These effects were
inhibited by MT2 specific antagonist- 4P-PDOT. The time periods of melatonin
treatment that increased the expression of osteogenic genes indicated both a sensitized
and desensitized receptors with respect to cAMP signaling, signifying two distinct
mechanisms of melatonin‟s action. Unlike the parathyroid hormone which is
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administered in intermittent doses to increase bone mass, a continuous melatonin
treatment may be effective in having an anabolic effect on bone.

Abstract 2: In this study we sought to understand the domains involved in the
function and desensitization of MT1 and MT2 receptors through site-directed
mutagenesis. Two mutations were constructed in the cytoplasmic C-terminal tail of
each receptor subtype- 1) A putative palmitoylation site ( a cysteine residue) in the Cterminal tail was mutated to alanine (MT1C7.72A and MT2C7.77A) and 2) the Cterminal tail in the was truncated (MT1Y7.64 and MT2Y7.64). Through confocal
microscopy, it was determined that the putative palmitoylation site did not play a role
in receptor internalization, however, this residue was essential for receptor function,
as determined by cAMP accumulation assays. Truncation of the C-terminal tail of
both receptors inhibited internalization as well as the cyclic AMP response,
suggesting the importance of the C-terminal tail in these receptor functions.
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Chapter 1
Treatment Effects of Melatonin on Differentiation of Human Mesenchymal Stem
Cells into Osteoblasts

1. INTRODUCTION
1.1

Bone and Osteoporosis
Bone remodeling is a constant and dynamic process.

The cells involved in bone

metabolism are of two types- osteoclasts that resorb old bone, and osteoblasts that form
new bone. Together these cells form the „bone metabolism unit‟. The formation of new
bone and the resorption of old bone are tightly coupled to each other. Bone remodeling is
initiated by osteoclasts which attach to old bone and erode the bone matrix. Once the
osteoclasts leave the unit, osteoblasts are recruited to this site and they start to fill up the
cavities formed by the osteoclasts, thus forming new bone in the process (Christenson,
1997; Manolagas, 2000).
An imbalance between the osteoclasts and osteoblasts equilibrium can lead to
osteoporosis, a disease characterized by a decrease in bone density and an increase in risk
of fractures. Approximately 10 million Americans have osteoporosis, out of which 80%
are women . One of the primary causes of osteoporosis in women is estrogen deficiency
with age or menopause (Lindsay et al., 1976; Horsman et al., 1977; Lufkin and Ory,
1989; Christiansen, 1993).
Most treatments for osteoporosis aim at preventing further bone loss by inhibiting
the activity of osteoclasts by use of bisphosphonates, calcitonin, selective estrogen
receptor modulators and supplementing one‟s diet with calcium and/ or vitamin D.
(Delmas, 2002; Uebelhart et al., 2003; Ishida and Kawai, 2004). These therapies have
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anti-resorptive mechanisms and as such, they do not increase bone mineral density. As
the scope of these therapies is limited by their inability to form new bone, there is a need
to discover newer therapies that will have anabolic effects on the bone. The only FDA
approved treatment that can build new bone by targeting the proliferation, differentiation,
and activity of osteoblasts is teriparatide PTH 1-34 (recombinant human 1-34 parathyroid
hormone; brand name: FORTEO) (Rosen and Bilezikian, 2001; Brixen et al., 2004). This
treatment requires daily subcutaneous injections of the peptide for many years.
A decrease in the hormone melatonin in serum with age has been related to
increase in risk of osteoporosis (Sandyk et al., 1992; Ostrowska et al., 2001b; Cardinali et
al., 2003). Melatonin has been shown to enhance differentiation of osteoblasts in various
cell models and it could prove to be a novel anabolic therapy for osteoporosis (Roth et al.,
1999; Radio et al., 2006; Satomura et al., 2007). Also, melatonin has been shown to
inhibit osteoclast activity (Suzuki and Hattori, 2002). The objective of this study was to
determine the critical time periods of melatonin exposure that cause differentiation of
osteoblasts and to study the various genes that are involved in this process.
1.2

Melatonin Synthesis
Melatonin is a hormone released from the pineal gland in response to darkness.

Melatonin concentrations vary in different body fluids, in different cells, in different sub
cellular organelles and in different organisms (Reiter and Tan, 2003). Melatonin
production in the body varies with the time of the day, with highest production being in
darkness. The levels of melatonin persist for longer periods of time during the winter
months (Witt-Enderby et al., 2003). In healthy human subjects, the average maximum
levels attained in the plasma of adults are around of 60 to 70 pg/ml. The levels begin
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increasing around 9-10 pm and remain high till 7-9 am. Peak concentrations are attained
between 2 am to 4 am (Zawilska et al., 2009).
Melatonin is synthesized in the pineal gland from serotonin. Serotonin is
converted to N- acetyl serotonin by the action of enzyme serotonin N-acetyl transferase.
N-acetyl serotonin is acted on by hydroxyindole O-methyltransferase to form melatonin
(Hickman et al., 1999; Schomerus and Korf, 2005).

N-acetyl transferase is the key

regulatory enzyme in this biosynthetic pathway and changes in its levels reflect changes
in melatonin production (Zawilska et al., 2009). The activity of this enzyme in mammals
in controlled by a master pacemaker circadian clock located in the suprachiasmatic
nucleus (SCN) in the anterior hypothalamus (Weaver, 1998; Reppert and Weaver, 2002).
Light is the most important signal that regulates the activity of N-acetyl
transferase and consequently melatonin production and release in the body. In mammals,
the pineal gland itself is not photosensitive, but it can „sense‟ the light and darkness
through a multi-synaptic pathway that connects the SCN with the pineal gland (Korf et
al., 1998). The final part of this pathway consists of sympathetic nerve fibers that
innervate the pineal parenchyma and release norepinephrine (NE) in a circadian manner
at night. SCN receives the photic information from the retina resulting in the release of
NE from the nerve fibers to bind the α1 and β1-adrenergic receptors on the pinealocytes.
The activation of α1 receptors lead to increases in intracellular calcium concentration
whereas the activation of β1 receptors lead to increases in intracellular cyclic AMP and
protein kinase A. Both these changes cause phosphorylation of transcription factors
CREB (cAMP regulatory element-binding protein) which induces the transcriptional
production of N-acetyltransferase enzyme (Romero et al., 1975; Chansard et al., 2005;
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Schomerus and Korf, 2005). Thus, the synthesis of N-acetyl transferase is regulated by
the light/ dark cycle.
The N-acetyl transferase production is also influenced by circadian rhythms,
independent of lighting conditions (Schwartz et al., 2009). The clock genes Per1 and
Per2 and two mammalian cryptochrome (Cry) genes, Cry1 and Cry2 in the rat pineal
gland are expressed in circadian fashion and are responsible for the self-sustaining
rhythm generating capacity of the SCN, in the absence of light (Lincoln et al., 2002).
The nocturnal release pattern of melatonin is the result of both circadian control
and light-inhibition of its synthesis (Fig. 1).
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Figure 1: Fluctuations in Melatonin Levels over a 24 h Period in humans
The average maximum levels attained in the plasma of adults are around of 60 to 70
pg/ml. The levels begin increasing around 9-10 pm and remain high till 7-9 am. Peak
concentrations are attained between 2 am to 4 am. The release pattern of melatonin is the
result of both circadian control and light exposure, as explained in text.
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1.3

Mechanisms of Action of Melatonin in Cells

1.3.1 Receptor Dependent Actions of Melatonin
Melatonin may bind to G-protein coupled receptors designated as MT1 and MT2
receptors or the binding site belonging to the quinone reductase 2 family of detoxifying
enzymes, designated as MT3 receptor (Nosjean et al., 2000; Delagrange et al., 2003;
Witt-Enderby et al., 2006). Both MT1 and MT2 receptors are coupled mainly to Gi
proteins that upon activation cause an inhibition of adenylyl cyclase enzyme in the cells
(Grant et al., 2009). This decrease in second messenger cyclic AMP (cAMP) levels,
PKA levels and CREB phosphorylation (McNulty et al., 1994; Witt-Enderby et al.,
2003). The activation of Gi proteins can cause the dissociation of the Giαβγ into Giα-GTP
and Giβγ. Giβγ may transactivate the epidermal growth factor receptors (EGFR) and the
activation of downstream effectors MEK and ERK. Activation of Gi may also result in
the internalization of the receptors through binding of β-arrestin-2 and subsequent
activation of MEKs and ERKs. The activation of the MAPK pathway has been linked to
an increase in cell differentiation (Ahmed et al., 2003; Radio et al., 2006; Bondi et al.,
2008; Grant et al., 2009).
MT1 and MT2 receptors are also coupled to Gq proteins, that upon agonist binding
causes an activation of phospholipase C, which hydrolyzes phosphatidylinositol 4, 5bisphosphate (PIP2) to form inositol 1, 4, 5-trisphosphate/ Ca2+ and diacylglycerol
(Brydon et al., 1999; MacKenzie et al., 2002). Activation of MT1 receptors may inhibit
the formation of early gene products- c-fos and c-jun (Ross et al., 1996). The MT2
melatonin receptor, in addition to coupling with Gi or Gq proteins, is able to inhibit the
soluble guanylyl cyclase pathway (Petit et al., 1999).
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The MT1 melatonin receptor is expressed in the suprachiasmatic nucleus of the
hypothalamus, pars tuberalis, retina and cardiac vessels (Witt-Enderby et al., 2003). MT2
receptors are expressed in the retina, hippocampus, SCN, and cerebellum (Dubocovich et
al., 2003; Alarma-Estrany and Pintor, 2007). MT3 binding site is present in a wide
variety of mammals and tissue, with highest receptor amounts and activity detected in the
liver and kidney (Nosjean et al., 2001).
1.3.2 Receptor Independent Actions of Melatonin
Melatonin is capable of acting independently of the melatonin receptors.
Melatonin is highly lipophilic and able to traverse the plasma membranes of the cells and
bind to cytosolic proteins like calmodulin to regulate Ca2+ signaling pathways (BenitezKing et al., 1993; Dai et al., 2002). Melatonin inhibits calmodulin activity by preventing
calcium binding, and causes a decrease in adenynlyl cyclase activity to decrease CREB
protein activity and cAMP response element (CRE)-containing genes. Besides
attenuating CRE- containing genes, melatonin, through an inhibition of calmodulin
dependent adenylyl cyclases, can inhibit ERE- containing genes by inhibiting the binding
of estrogen receptors (ER-α) to estrogen response elements. Melatonin can also down
regulate estrogen synthesis by decreasing the release of gonadotropins (Roy et al., 2001)
or by inhibiting aromatases (Molis et al., 1994; Rato et al., 1999; Witt-Enderby et al.,
2003; Grant et al., 2009). These anti-estrogenic mechanisms suggest that melatonin may
have an important role in bone metabolism, since estrogen is critical for maintaining bone
mass in women. Estrogen modulates osteoclast activity and a loss of estrogen in body,
either through menopause or tamoxifen therapy increases the risk of osteoporosis
(Srivastava et al., 2001; Saintier et al., 2006; Robinson et al., 2009).
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Besides the actions listed above, melatonin is also a direct free radical scavenger.
It can directly detoxify free radical species, increase the activity of anti-oxidative
enzymes and increase efficiency of mitochondrial oxidative phosphorylation to improve
mitochondrial metabolism i.e., by avoiding electron leakage, enhancing complex I and
complex IV activities, or by having a synergizing effect with other antioxidants (Reiter et
al., 2003; Hardeland and Pandi-Perumal, 2005; Grant et al., 2009). The by- products
generated by the free radical scavenging effects of melatonin are also free radical
scavengers themselves. This radical scavenger on radical scavenger effect makes
melatonin a more potent free radical scavenger than glutathione (Reiter et al., 2007b).
The binding site of melatonin termed as MT3 receptor is a detoxifying and antioxidant
enzyme quinine reductase enzyme, the activation of which may also be responsible for
some of the melatonin‟s anti-oxidative effects (Nosjean et al., 2000; Witt-Enderby et al.,
2006; Tan et al., 2007).
1.4

Melatonin and Bone
Melatonin has been implicated in osteogenesis and osteolysis through a variety of

mechanisms. Its osteogenesis or bone forming properties have been attributed to its
effects on osteoblasts to either induce their differentiation (Roth et al., 1999; Radio et al.,
2006) or proliferation (Nakade et al., 1999; Satomura et al., 2007), inhibit osteoclast
activity (Koyama et al., 2002; Suzuki and Hattori, 2002) (Cardinali et al., 2003). A
summary of various effects of melatonin on bone status is given below.
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1.4.1 Human and Animal Studies
The prevalence of osteoporosis in women is 10 years following menopause,
suggesting that circulating estrogen levels play a critical role in preventing bone loss in
women. Besides estrogen, melatonin levels decrease with age and after menopause.
These findings suggest that melatonin may be an important factor in the development of
post-menopausal osteoporosis in women (Waldhauser et al., 1984; Sack et al., 1986).
Bone metabolism has a diurnal rhythm which can be attributed to melatonin production
in the body (Hassager et al., 1992; Greenspan et al., 1997; Heshmati et al., 1998;
Ostrowska et al., 2003). Exposure to artificial light at night is related to decreases in
plasma melatonin levels (Graham et al., 2001). In a study performed on women who
worked night shifts for more than 20 years, there is a significantly increased risk of wrist
and hip fractures compared with women who never worked at night (Feskanich et al.,
2009). It is known that exposure to artificial light (as in the case of night shift workers) at
night is related to decreases in plasma melatonin levels (Graham et al., 2001),. It could
be assumed that increases in melatonin in the body can be protective against osteoporosis.
Likewise, a negative correlation between the salivary melatonin levels and biochemical
markers of bone resorption is found in post-menopausal obese women, again supporting
that melatonin may be an endogenous inhibitor of osteoclast activity (Ostrowska et al.,
2001a).
Several animal studies suggest that a relationship between melatonin levels and
bone metabolism exists. Early studies demonstrate that pinealectomy affects the
morphology of the parathyroid gland, a gland that controls calcium in the bone (Chen et
al., 1990). Pinealectomy (removal of melatonin source) of chickens results in lower bone
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mineral density in the vertebral column. These data suggest that endogeneous melatonin
may have an osteoinductive effect on bone formation. Histological changes in
pinealectomized chickens show that the total number of osteocytes is significantly lower
than control, suggesting that melatonin enhances osteocyte proliferation in the cervical
vertebra. (Turgut et al., 2005). High night-time levels of melatonin are found in bone
marrow of rats and humans (Tan et al., 1999; Conti et al., 2000), and this could be a
contributing factor in the differentiation of precursor cells to osteoblasts. In
ovariectomized rats, there is an increase in bone resorption marker urinary
deoxypyridinoline compared to non- ovariectomized rats. Ovariectomy is often used in
experimental animals to mimic the conditions of post-menopausal osteoporosis. This
effect is not observed in rats given an exogenous melatonin (25 mg/ml) dose in drinking
water (Ladizesky et al., 2001). In another study on bilaterally ovariectomized rats, a
decrease in trabecular thickness of the vertebra and a decrease in both trabecular and
cortical thickness of the femur occurs that is prevented by exogenous melatonin (10
mg/kg) administration (Uslu et al., 2007). In male mice administered melatonin, a
significant increase in bone mineral density and bone mass occurs compared to mice
treated with vehicle alone (Koyama et al., 2002). These studies support the role of
melatonin in bone remodeling processes.
Several studies reported a relationship between melatonin levels and scoliosis (a
bone deformity characterized by curvature of spine). Removal of the pineal gland results
in the development of scoliosis in chickens that has anatomical characteristics similar to
those of human idiopathic scoliosis (Machida et al., 1993). In another study using
C57BL/6J mice, it is shown that bipedal ambulation combined with melatonin deficiency
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induces scoliosis. Ambulation in a mouse strain, which displayes normal melatonin
rhythms, also results in scoliosis although at a rate slower than in C57BL/6J mice
(Oyama et al., 2006). C57BL/6, a common strain of laboratory mice, is also a natural
knock-down model for melatonin synthesis in the pineal gland, where N-acetyl
transferase function is compromised because of a point mutation in its gene (Roseboom
PH, 1998). From these studies, it is hypothesized that bipedal primates, like humans,
may develop scoliosis when melatonin levels in the body are depressed (i.e., aged or
light-at-night exposed individuals). However, this hypothesis is not supported in rhesus
monkeys, where pinealectomy and ambulation do not cause scoliosis (Cheung et al.,
2005). Nonetheless, in human adolescents with idiopathic scoliosis, serum melatonin
levels are significantly lower compared to controls (Sadat-Ali et al., 2000). Also,
osteoblasts from patients with adolescent idiopathic scoliosis show an impairment of
melatonin- induced inhibition of forskolin stimulated adenylyl cyclase activity (Moreau
et al., 2004). These data suggest that melatonin, acting through melatonin receptors and
cAMP dependent pathway in osteoblasts, protect against scoliosis.

Oral melatonin

treatment in patients with adolescent idiopathic scoliosis and low melatonin levels delays
the progression of this disease (Machida et al., 2009). These studies support a role for
melatonin in preventing pathogenic bone conditions such as osteoporosis and scoliosis.
1.4.2 In- Vitro Studies
Various in-vitro studies have demonstrated the relationship between melatonin
and bone. For example, murine and human bone marrow cells have been shown to have
high concentrations of melatonin and serotonin-N-acetyltransferase activity, the rate
limiting enzyme in melatonin synthesis (Conti et al., 2000). Melatonin significantly
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increases the proliferation of HOB-M (normal human bone cells) cells and SV-HFO
(human osteoblastic cell line) cells. Melatonin causes a dose-dependent reduction in both
osteoclastogenesis and osteoclast activity to reduce the number of resorption pits and
average pit area/pit in mouse bone marrow cells (Koyama et al., 2002). Inhibition of
osteoclast activity, as measured via a reduction in tartrate-resistant acid phosphatase
activity, is observed in cultures of goldfish scales (an in-vitro model for studying bone
metabolism) (Suzuki and Hattori, 2002).
Mechanisms underlying melatonin-induced effects on osteoblast are not clear, and
this may be dependent on the choice of the model system. For example, in human bone
cells in culture, melatonin increases the expression of procollagen type I c-peptide, but is
without effect on alkaline phosphatase and osteocalcin, the proteins involved in formation
of bone (Nakade et al., 1999). However, in cultures of goldfish scales, melatonin
decreases the expression of alkaline phosphatase and mRNA levels of estrogen receptor
and of insulin-like growth factor- a growth factor involved in bone metabolsim (Suzuki
and Hattori, 2002; Suzuki et al., 2008a). Positive effects on osteoblast differentiation are
seen in pre-osteoblast and rat osteoblast-like osteosarcoma cell lines where treatment
with 50 nM melatonin show an increase in bone marker proteins like alkaline
phosphatase, osteopontin and osteocalcin. The effect of melatonin is inhibited by the
melatonin receptor antagonist luzindole and by pertussis toxin, suggesting the
involvement of melatonin transmembrane receptors (Roth et al., 1999). Melatonin
increases the differentiation of human mesenchymal stem cells to osteoblasts, as
measured by an increase in alkaline phosphatase activity (Radio et al., 2006). In a similar
study, melatonin enhances the proliferation and differentiation of human osteoblasts, and
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promotes the gene expression of type I collagen, osteopontin, bone sialoprotein, and
osteocalcin (Satomura et al., 2007). Melatonin also stimulates osteogenic differentiation
in bone marrow stem cells as measured by alkaline phosphatase activity and staining for
calcium deposition (Zaminy et al., 2008). Thus, it can be seen that melatonin influences
bone metabolism in-vitro, similar to its effects in-vivo.
1.5

Signaling Events Governing Osteoblast Differentiation
The differentiation of mesenchymal stem cells into osteoblasts is controlled by

complex activities involving signal transduction pathways that are not fully understood.
Mesenchymal stem cells are obtained from the bone marrow and are multipotent with the
ability to differentiate into osteoblasts, chondrocytes and adipocytes (Pittenger et al.,
1999). Stem cells are activated by tightly regulated and complex signals. Following
initial lineage commitment by the stem cell, the cell divides giving rise to another stem
cell (self-renewal) and a committed osteoprogenitor. The mature osteoprogenitor is able
to divide to form pre-osteoblasts, which is an intermediate stage of differentiation. At
this stage, the pre-osteoblasts begin to express certain bone markers like alkaline
phosphatase (ALP), parathyroid hormone and type l collagen. The pre-osteoblasts
undergo further differentiation to form mature osteoblasts, which express alkaline
phosphatase, osteopontin, bone sialoprotein, and osteocalcin (Thomas and Kansara,
2006). The last stage of differentiation is the osteocyte. A range of cytokines modulate
the differentiation processes, like BMP (bone morphogenetic proteins) and TGF-β
(transforming growth factor-β) (Huang et al., 2007). These proteins are frequently used
as markers for osteoblast differentiation, with the most common ones being alkaline
phosphatase, osteocalcin, bone morphogenetic proteins, runt-related transcription factor -
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2, and bone sialoprotein and type-1 collagen. Different stages of differentiation of human
mesenchymal stem cells into osteoblasts are represented in Fig. 2.

Stem cell

early

+
self- renewal

Immature
Osteoprogenitor

Mature
Osteoprogenitor
Preosteoblasts

intermediate

osteoblasts

osteocytes

late

Figure 2: Diagrammatical Representation of the Different Stages of Differentiation
of human Mesenchymal Stem cells into Osteocytes
Adapted from(Thomas and Kansara, 2006).
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The most important transcriptional regulators of osteoblast differentiation are
Runt-related transcription factor 2 (RUNX-2) and osterix (Official name: SP7). Knockout
mice for these genes demonstrate a complete lack of ossification (Komori et al., 1997;
Nakashima et al., 2002). RUNX-2 regulates the transcription of other bone specific genes
like osteocalcin and osteopontin (Ducy et al., 1999).
Bone morphogenetic proteins (BMPs) are members of the TGF-β superfamily
(Chen et al., 2004). The most readily detectable BMPs are BMP-2, -4 and -6 (Huang et
al., 2007). BMPs bind to BMP receptors and signal downstream via Smad dependent or
Smad independent pathways (Derynck and Zhang, 2003). Smads are the downstream
signal transducers for the serine/threonine kinase receptors. Upon BMP stimulation and
activation by TGFR receptors, receptor-regulated Smads (R-Smads) are phosphorylated,
which in turn, form complexes with another type of Smad called common-partner Smads
(Co-Smads). The R-Smad/ Co-Smad complexes then translocate into the nucleus where
they interact with various transcription factors to regulate transcription of osteoblast
specific genes (Chau et al., 2009). One of the transcription factors in the nucleus that is
induced through this pathway is RUNX-2 (Lee et al., 2003; Miyazono et al., 2005).
BMPs can also act through Smad independent pathways to activate MAPK
(mitogen activated protein kinases) pathway and activate proteins ERK (Extracellular
signal-regulated kinases) , JNK (c-Jun N-terminal kinases) and p38 in osteoblastic cells
(Derynck and Zhang, 2003; Guicheux et al., 2003). ERK could activate RUNX-2
downstream and increase its transcription activity (Ge et al., 2007). The MAPK pathway
has been reported to be involved in differentiation of osteoblasts (Ahmed et al., 2003), as
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measured by bone marker proteins alkaline phosphatase and osteocalcin (Ahmed et al.,
2003; Guicheux et al., 2003; Radio et al., 2006).
Another signaling mechanism in osteoblast differentiation is the activation of
Wnt-β-Catenin pathway. Wnts are released from the signaling cells and are ligands for
FZD (membrane spanning frizzled receptor) (Huang et al., 2007). The activated receptor
causes a downregulation of glycogen synthase kinase 3 and subsequent hypophosphorylation of its substrate β-Catenin. β- Catenin then translocates to the nucleus to
activate osteoblastic gene expression of genes like RUNX-2 and osteocalcin (Day et al.,
2005). The various signaling pathways are depicted in Fig. 3.
In addition to the aforementioned pathways, various other signaling mechanisms
i.e., fibroblast growth factors, Notch receptors, parathyroid hormone and molecules like
Indian hedgehog are also involved in osteoblast differentiation (Huang et al., 2007; Chau
et al., 2009). Adding to the complex mechanisms of bone differentiation is the fact that
many of these pathways interact with each other. For example. the BMP-Smad pathway
and the Wnt-β-Catenin pathway have been reported to interact in osteoblasts (Guo and
Wang, 2009).
In the present study, various genes mentioned above were investigated to
determine which of these pathways is influenced by melatonin.
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Figure 3: Important Signaling Mechanisms Involved in Osteoblast Differentiation
Bone morphogenetic proteins can increase the expression of RUNX-2 and osterix through
Smad dependent pathways or through activation of MAPK. RUNX-2 may also be
activated through Wnt binding to FZD receptors. RUNX-2 and osterix expression is vital
for osteogenesis.
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1.6

Mechanisms of Action of Melatonin on Osteogenesis
Melatonin‟s actions on bone involve many different signal transduction

mechanisms comprising osteoclasts, osteoblasts, and interaction with estrogen (WittEnderby et al., 2006).

RANKL-RANK-OPG pathway: Studies have shown that melatonin inhibits osteoclast
formation and activity and thus prevents excessive bone resorption. One of the main
mechanisms for this is the interaction of melatonin with the RANKL-RANK-OPG
pathway. Osteoblasts and stromal stem cells express a protein called receptor activator of
NF-κB ligand (RANKL), which binds to its receptor, RANK, on the surface of
osteoclasts and their precursors. The RANK-RANKL interaction increases the
development of osteoclasts and their activity. Osteoprotegerin (OPG) is secreted by
osteoblasts and protects the skeleton from excessive bone resorption by acting as a decoy
by binding to RANKL and preventing it from interacting with RANK (Wada et al., 2006;
Boyce and Xing, 2007) (Fig. 4). In a study using mouse osteoblastic MC3T3-E1 cells, it
was shown that melatonin (5-500 µM) decreases RANK mRNA and increases mRNA
and protein levels of osteoprotegerin. This study demonstrates that melatonin increases
bone mass and reduces bone resorption by down-regulating RANK-mediated osteoclast
formation and activation (Koyama et al., 2002; Cardinali et al., 2003).
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Bone resorption

Figure 4: Schematic Representing Melatonin’s Effects on Osteoclasts
Pre-osteoclasts express receptor RANK (receptor activator of NF-κB) on their surfaces.
Activation of these receptors by protein RANKL, secreted by osteoblasts, lead to
formation of active osteoclasts. OPG (osteoprotegerin), another protein secreted by
osteoblasts acts as a decoy for RANKL and inhibit the formation of osteoclasts.
Melatonin increases the expression of OPG, thus inhibiting osteoclastogenesis. Active
osteoclasts secrete free radicals that can be scavenged by melatonin.
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Anti-oxidant mechanisms of melatonin: Osteoclasts generated free radicals facilitate the
destruction of calcified tissue, thus assisting in bone remodeling (Fraser et al., 1996;
Berger et al., 1999; Yang et al., 2001). The accumulation of reactive oxygen species
(ROS) is shown to increase gene transcription of RANKL and osteoclastogenesis by
activation and nuclear accumulation of ERK, followed by phosphorylation of STAT3
protein (signal transducer and activator of transcription). This effect is reversed by the
anti-oxidant N-acetyl cysteine (Chen et al., 2008b). In a case control study in healthy and
osteoporotic individuals, oxidative stress was found to be an independent risk factor for
osteoporosis measured through various oxidative markers (Sanchez-Rodriguez et al.,
2007). These findings raise the possibility of preventing or treating bone loss by
treatment with anti-oxidants (Banfi et al., 2008). As mentioned earlier, melatonin has
free radical scavenging and anti-oxidant properties (Reiter et al., 2001; Reiter et al., 2002;
Reiter et al., 2007a; Tengattini et al., 2008), thus, the inhibitory effect of melatonin on
osteoclasts could partly be due to these effects (Fig. 4).

Involvement of melatonin receptors and MAPK pathway: Positive effects of melatonin
on osteoblast differentiation have shown an involvement of the MT2 receptors, activation
of EGFR (epidermal growth factor receptor) and downstream activation of MAPK in
human mesenchymal stem cells. It has been proposed that chronic activation of MT2
receptors by melatonin results in MT2R phosphorylation, and internalization by binding
to β-arrestin. The activation of melatonin receptors by melatonin also leads to the
activation of Gi proteins resulting in the dissociation of the Gi into its Giα and Gβγ subunit.
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It is hypothesized that Gβγ subunits activate matrix metalloproteinases within the
membrane resulting in HB-EGF (heparin bound- epidermal growth factor) shedding to
release EGF and activate the EGFR. β-arrestin is thought to form a scaffold with these
proteins and ultimately cause MAPK (ERK1/2) activation. Activated MAPKs like p38,
and ERK1/2 can promote the expression of differentiation markers of osteoblasts (Suzuki
et al., 1999; Rawadi et al., 2001; Radio et al., 2006; Matsushita et al., 2009).

Involvement of estrogen receptor signaling: One of the putative causes of postmenopausal osteoporosis is a decline in estrogen levels. There is also a decline in
melatonin levels with age and it is speculated that both these factors may combine to
increase the risk of fractures in post menopausal women (Lindsay et al., 1976; Horsman
et al., 1977; Waldhauser et al., 1984; Sack et al., 1986; Christiansen, 1993). Several
investigators studying the anti-cancer properties of melatonin have demonstrated that
melatonin has an inhibitory effect on estrogen receptor signaling mechanisms, as
mentioned previously (Grant et al., 2009). Some studies have shown that melatonin is
able to reverse the decrease of bone markers (trabecular thickness of vertebra and femur
urinary deoxypyridinoline, a marker of bone resorption) induced by ovariectomy in
animals (Ladizesky et al., 2001; Uslu et al., 2007). In a study by Suzuki and Hattori, it is
shown that melatonin treatment depresses markers of osteoblastic differentiation
including mRNA expression of estrogen receptor and insulin-like growth factor in scales
of goldfish (Suzuki and Hattori, 2002). These findings are in contrast to most published
studies examining the effect of melatonin on bone cell differentiation markers. The
contradictory results of this study could be attributed to many reasons. For example, this
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study was performed in scales of goldfish where ERβ seems to be largely related with
osteoblastic activity and differentiation (Yoshikubo et al., 2005). The inhibitory actions
of melatonin on ER has been reported mainly through ERα and not ERβ in MCF-7 cells
(Martinez-Campa et al., 2006; Grant et al., 2009). Also, the study by Suzuki and Hattori
reports an increase in osteoclast differentiation along with a decrease in osteoblast
differentiation, an effect not seen in most other model systems. In light of most other
published reports, both melatonin and estrogen have positive effects on bone formation,
but exactly how each modulates the other‟s effect remains to be determined.

Epigenetic processes: Epigenetic processes contribute to development and differentiation
of cells (Strathdee et al., 2004). Epigenetic gene regulation involves two main classes of
molecular mechanisms: DNA methylation by DNA methyltransferases and histone
modifications by histone deacetylases and histone acetyl transferases. DNA
methyltransferases add methyl groups to the cytosines within CpG dinucleotides. The
methylation of CpGs within genes serves to „silence‟ their expression. Acetylation of
histones by histone acetyl transferases activates gene transcription by moving apart
histone proteins to allow for the general transcriptional apparatus (i.e., RNA polymerase
II) to bind to promoter regions and initiate gene transcription. By contrast, deacetylation
of histones by histone deactylases, keeps histones tightly bound, thus preventing access
of RNA polymerase II and accessory proteins to bind to and activate gene transcription.
DNA methylation patterns are reported to be essential for normal cell development and
differentiation (Arney and Fisher, 2004).

Nuclear factor-κB (NF-κB) (RANK), which is

involved in melatonin‟s positive effect on bone formation as described previously, is
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involved in activation of CYP19 gene (Koyama et al., 2002). This gene, also called
cytochrome P450 19, encodes for aromatase enzyme, which is responsible for a key step
in the biosynthesis of estrogens (Nelson DR, 1993 ). It has been speculated that
melatonin may cause methylation of CYP19 gene or deacetylation of CYP19 histone
leading to gene silencing, thus demonstrating melatonin‟s involvement in epigenetic
processes (Cai et al., 2007; Korkmaz et al., 2009). Melatonin may play a role in
inhibiting osteoclasts and promoting osteoblast differentiation through epigenetic
modifications of genes involved in bone development. A recent study has demonstrated
that differentiation of neural stem cells by melatonin increases histone deacetylase
mRNA levels and histone H3 acetylation (Sharma et al., 2008). Future work assessing
the role of melatonin on epigenetic mechanisms may provide valuable mechanistic data
underlying melatonin‟s effects on their differentiation into osteoblasts.
1.7

Human Adult Mesenchymal Stem Cell Model
The present study utilizes human mesenchymal stem cells as a model to study the

effects of melatonin on osteoblast differentiation. Human mesenchymal stem cells are
bone marrow-derived multipotent precursors capable of differentiating into chondrocytes,
adipocytes, or osteoblast terminal cells (Pittenger et al., 1999). These cells are being
studied for their potential in tissue regeneration (Huang and Li, 2008; Arthur et al., 2009;
Karp and Leng Teo, 2009).
In the present study, human mesenchymal stem cells were cultured in osteogenic
medium to drive their lineage to osteoblasts. Different time periods of melatonin
exposure were studied to define the type of melatonin exposure required to drive highest
osteoblast differentiation (section 3.1). Elucidating which type of melatonin exposure is
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most effective will provide important clues as to the molecular mechanisms underlying
melatonin‟s effects on bone metabolism, and also provide indications to determine the
optimum method of administering melatonin to patients. Various osteogenic genes were
also investigated in melatonin treated cells to determine the inter-cellular pathways
involved in this process (section 3.10).
2. MATERIALS AND METHODS
2.1

Cell Culture
Multipotent adult human mesenchymal stem cells (hAMSCs) were were

maintained at 370C and 5% CO2. Cells were grown and passaged in mesenchymal stem
basal cell medium containing 10% bovine growth serum (containing L-glutamine)
(Lonza, Walkersville, MD). This medium was termed as OS- medium and was intended
to promote hAMSCs proliferation, but not to induce differentiation into osteoblasts. For
passing the cells, the cells were grown until they were 80% confluent in 75 cm2 cell
culture flasks, washed with 1 ml trypsin, then detached from the plate using 2 ml trypsin
for 2-3 minutes. The cells were seeded using 3 ml trypsinate and 7 ml OS- medium. For
various assays, the cells were seeded at an initial density of 3 X 103 cells/cm2 in tissue
culture plates, dishes or flasks.
For the studies assessing melatonin-dependent induction of osteogenesis, the cells were
incubated in stem cell growth medium supplemented with 0.1 µM dexamethasone, 10
µM β-glycerphosphate and 50 µM ascorbate (OS+ medium) for the indicated times. This
medium has been shown to enhance alkaline phosphatase (ALP) activity (a marker for
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osteoblast differentiation) in several immature bone progenitor models (Cheng et al.,
1994; Otsuka et al., 1999; Shiga et al., 2003; Jorgensen et al., 2004; Radio et al., 2006).
2.2

Treatment Groups
The treatment consisted of two study designs-Study Design A and Study Design

B. The total time frame of treatment in both designs was 21 d. In the control group for
both Study Designs A and B, the cells were incubated in OS+ for 21 d (days). In Study
Design A, 50 nM melatonin was added to the medium before the end of the total period
for the indicated times (2d, 5d, 10d, 14d and 21d). In Study Design B, 50 nM melatonin
was added to the medium on day 1, the cells were treated with melatonin for the indicated
times (2d, 5d, 10d, 14d and 21d), and then melatonin was removed and cells were
cultured in control media without melatonin till a total period of 21 d. Media was
removed and fresh media containing melatonin was replaced every 2 days. These two
study designs were performed as such, so as to determine when melatonin exerts its
maximal effect in stimulating osteogenesis- at a later stage of osteoblastic differentiation
(Study Design A) or the initial phase of differentiation (Study Design B). These study
designs and treatment groups would also indicate if short term or longer melatonin
exposure was favorable to osteogenesis. The study designs are depicted
diagrammatically in Fig. 5.
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Figure 5: The Study Design
All treatments were carried out for 21 d. The hAMSCs in the control groups in both
study designs were treated with OS+ medium for 21 d (broken lines). The treatment
groups consisted of hAMSCs treated with OS+ medium (21 d) in addition to 50 nM
melatonin (solid lines) for indicated times. In Study Design A, melatonin was added to
the medium towards the end of the 21 d culture. In Study Design B, melatonin was
added to the medium at the beginning of the 21 d culture. Media was removed and fresh
media containing melatonin was replaced every 2 days.
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For the antagonist studies, 1µM of MT2 specific antagonist 1 µM 4P-PDOT
(Tocris, Ballwin, MO) was added to the medium in addition to 50 nM melatonin for the
indicated times.
For the experiment investigating the effect of varying the duration of osteogenic
medium (OS+) prior to the 2 d melatonin exposure, the cells were first incubated in OS+
medium for 11d, 13d, 15d, 17d or 19d and then combined with melatonin for additional
2d towards the end of the OS+ exposure, as indicated in Fig. 6.

21d
19d
17d
15d
13d

Figure 6: The Study Design for Investigating the Effect of Varying the Duration of
OS+ Medium on Melatonin-Induced Osteoblast Differentiation
The hAMSCs were exposed to OS+ medium for varying times prior to the 2 d melatonin
exposure. Dotted lines represent total exposure to OS+ medium and solid lines represent
melatonin exposure. The cells were plated in OS- medium and the above treatments were
started the following day. Melatonin was added for 2 d towards the end of the treatments
with OS+ medium for indicated times.
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2.3

Alkaline Phosphatase Assay
To assess the activity of osteoblasts, ALP assays were performed. The ALP

activity was analyzed by measuring the rate of hydrolysis of p-nitrophenyl phosphate
disodium hexahydrate (pNPP) by the hAMSCs following treatments. The hAMSCs were
plated at a density of 3 X 103 cells/cm2 in 12 well plates as described earlier and treated
according to Study Design A or B for 21 d or as indicated. At the end of the time period,
the cells were washed 3 times with 0.5 ml PBS to remove osteogenic medium and
melatonin. After the washings, 0.5 ml of PBS was added to the wells; the cells were
scraped into PBS, transferred to microcentrifuge tubes and then centrifuged for 10 min.
The whole pellet was then reconstituted with 200 µl PBS. The pNPP product was
generated using a p-nitrophenol phosphate stock (Sigma, St. Louis, MO) and analyzed
according to the manufacturer‟s instructions. A yellow end product was obtained that
was analyzed spectophotometrically at 405 nM using a microplate reader. The results
were compared against a standard curve. ALP activity was normalized against total
protein, determined via BSA assay (Pierce, Rockford, IL). A sample of calculations for
determining ALP activity is given in Appendix 12.1.
2.4

Quantitative Analysis of Osteogenesis
To quanitify the extent of calcium deposition by osteoblasts, alizarin red stains

were performed. Briefly, the hAMSCs were plated in 24 well plates as described earlier
and exposed to melatonin as described in Fig. 5. Following the 21 d treatments,
osteogensis quantitation was carried out using a commercial quantitation kit (Chemicon,
Temecula, CA), where the intensity of alizarin red staining was measured using a
microplate reader. A sample of calculations for quantitative analysis of osteogenesis is
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depicted in Appendix 12.2. At the end of the treatment periods, the cells were washed
and fixed in 70% ethanol for 15 min and then quantified by spectophotometry at 405 nM.
2.5

Qualitative Analysis of Osteogenesis
To assess the extent of osteoblast differentiation visually, alizarin red staining was

performed on cells following the melatonin treatment for 21 d as described in fig 5. The
hAMSCs were plated at a density of 3 X 103 cells/cm2 or 0.75 X 103 cells/cm2 in 10 cm2
dishes. Following the 21d exposures, the cells were washed with 0.5ml PBS and fixed in
10% formalin for 10 min at room temperature. The cells were then stained with 2%
alizarin red solution (Sigma Chemical Co., St. Louis, MO) for 10 minutes at room
temperature. Prior to viewing the stained cells under a light microscope at 400X, the
cells were washed 3 times with pure water.
2.6

Radioligand Binding Assays
To assess the melatonin receptor expression levels in differentiating hAMSCs, total

binding analysis using the radioligand 2-[125I]-iodomelatonin was performed. Briefly, the
hAMSCs were plated in 10 cm2 dishes and cultured for different times in medium
according to the Study Design A or B. After the completion of the treatment, the cells
were washed twice with 5 ml PBS, scraped in LIFT buffer (10 mM KPO4, 1 mM EDTA
at pH 7.4) and pelleted through centrifugation at 1500 rpm for 5 min. The cells were
resuspended in 5 ml of 50mM Tris (pH 7.4) solution and incubated at room temperature
for 1 hr with 500pM of 2-[125I]-iodomelatonin in the absence (total binding) and presence
(non-specific binding) of 1µM melatonin. Reactions were terminated by the addition of
ice-cold Tris-HCl solution (50 mM) and rapid filtration over glass-fiber filters presoaked
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in 0.5% polyethylenimine solution. Each filter was washed twice with 5 ml of ice cold
TRIS (50 mM) buffer. Radioactivity was determined in a gamma counter and total
specific binding of 2-[125I]-iodomelatonin was calculated by subtracting non specific
binding from total binding. Binding was converted to fmoles and then normalized per
mg protein. Protein determinations were made by the method of Bradford using Bio-Rad
protein assay reagents by comparing the values against a standard curve (Bio-Rad,
Hercules, CA).
2.7

cAMP Accumulation Assays
To assess melatonin receptor function in differentiating hAMSCs, cAMP assays

were performed using a direct cyclic AMP enzyme immunoassay kit (Assay Designs,
Ann Arbor, MI). Briefly, the hAMSCs were plated in 12 well plates at a density of 3 X
103 cells/cm2 and exposed to melatonin as described in Study Design A, except that
cAMP measurements were made following 2, 10 or 21 d melatonin exposure and then
compared to vehicle treated cells. After the treatment, the medium was aspirated, washed
with 0.5 ml PBS and then exposed to serum free media containing either 30 µM rolipram
alone (basal), 30 µM rolipram and 100 µM forskolin (maximal accumulation) or 30 µM
rolipram, 100 µM forskolin and 10 nM melatonin. The cells were then incubated for 20
min in an incubator at 370 C. Cyclic AMP accumulation was measured according to
manufacturer‟s instructions. To measure the decrease of cAMP with melatonin exposure,
forskolin was added to the culture medium to artificially increase the production of
cAMP. The decrease in cAMP accumulation by melatonin was measured as a function of
forskolin response. Melatonin mediated inhibition of forskolin-induced cAMP
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accumulation was measured in each set of cells and then expressed as a percentage of
forskolin response within each group.
2.8

Cell proliferation Assays
To assess the extent of proliferation in differentiating hAMSCs, the cell

proliferation assays were performed using CellTiter 96AQueous One Solution Cell
Proliferation Assay Kit (Promega, Madison, WI). Briefly, the hAMSCs were plated in
12-well plates at a density of 3 X 103 cells/cm2 and treated according to Study Design A
for the indicated times, except that measurements were made following 2, 10 or 21 d
melatonin exposure and then compared to vehicle treated cells. After the treatment, the
cells were washed twice with PBS, 200 µl of culture medium was added and cells were
scraped using a cell scraper. One hundred microliters of this cell suspension was
transferred to a 96 well plate and with 20 µL of the Cell Titer solution for 4 hr at 370 C.
The solution was read by spectophotometry at 405 nm according to manufacturer‟s
instructions.
2.9

RNA Extraction
To assess gene expression patterns of known osteoblast markers in differentiating

hAMSCs, quantitative real time RT-PCR was performed. Briefly, the hAMSCs were
plated in 10 cm2 dishes and treated according to Study Design A for the indicated times.
After the treatment, the cells were washed with PBS and scraped in 1 ml TRIZOL. Total
RNA was isolated and purified using the RNeasy RNA Extraction Kit (Stratagene, La
Jolla CA). The cell suspension was filtered using the manufacturer‟s pre-filter spin cups.
Seventy percent ethanol was added to the filtrate and the solution was then filtered
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through the filter spin cups to bind total RNA to the spin cup membranes. This RNA was
further purified by washing with a low salt and high salt solution according to the
manufacturer‟s instructions. RNA was quantified using a spectrophotometer at an optical
density of 260 nm. Purity was assessed by calculating the ratio of the optical density at
260 nm to the optical density at 280 nm. Samples having a purity ratio less than 1.8 or
greater than 2.1 were discarded and new RNA extracts were prepared.
2.10 RT-PCR Reactions
Total RNA (250 ng) was reverse transcribed into cDNA using ABgene ReverseiTTM 1st strand Synthesis kit (ABgene, Rochester NY). The cDNA were obtained using
random decamers as per manufacturer‟s instructions. Random decamers were chosen
over oligo(dT) primers, so that reverse transcription of the desired target region is not
dependent on its distance from the polyA tail. A no “RT reaction” was made for each
sample that contained RNA and all reagents except the transcriptase enzyme to ensure
that DNA was not contaminating the RNA.
2.11 Real-Time RT-PCR
Real-time RT-PCR was performed using cDNA samples in the iCycler using iQ
SYBR Green Supermix to quantify the levels of mtTFA (mitochondrial transcription
factor A); PGC-1α (PPAR coactivator-1 α); Pol γ (DNA polymerase γ); NRF-1 (nuclear
respiratory factor 1), PDK (pyruvate dehydrogenase kinase), PDH (pyruvate
dehydrogenase), LDH (lactate dehydrogenase), RUNX-2 (runt related transcription factor2), OC (osteocalcin), BMP-2 (bone morphogenetic protein-2), BMP-6 (bone
morphogenetic protein-6), ALP (alkaline phosphatase) genes . Forward and reverse
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primers were designed for each gene sequence using Primer3 and PrimerQuest (Rozen
and Skaletsky, 2000). Primer specificity for the target gene was verified by aligning
primer and gene sequences using NCBI nucleotide BLAST. All primers were designed
to span at least one intron/ exon boundary to ensure amplification of mRNA sequences
and greatly reducing replication of DNA sequences. Primer sequences were ordered
from Integrated DNA Technologies (Coralville, IA). Lyophilized primers were
resuspended using RNase/ DNase free water to a final concentration of 100 pmol/ µl.
Thermocycling reactions were was carried at 95 °C for 3 min followed by 50 cycles at 95
°C for 30 s (denaturation) and 60 °C for 60 s (annealing). Each well contained a final
volume of 25 µl. RT and no RT volumes were 0.5 µl in each reaction well. Forward and
reverse primers were used at a final concentration of 200 nM each. A total of 12.5 µl of
SYBR green mastermix was added to each reaction. A melt curve was performed after
each PCR reaction to ensure the presence of a single gene product. GAPDH was used as
the housekeeping gene. The ΔCt values were calculated for each sample by subtracting
the threshold cycle value (Ct) of GAPDH from the Ct value of gene of interest. Lower Ct
and ΔCt values indicate higher gene abundance. The fold change versus the control group
was calculated by the 2-ΔΔCt method (Livak and Schmittgen, 2001). A sample of
calculations for fold changes in gene expression is depicted in Appendix 12.3. For genes
involved in mitochondrial biogenesis and anaerobic metabolism, i.e., mtTFA
(mitochondrial transcription factor A), PGC-1α (PPAR coactivator-1 α) and Pol γ (DNA
polymerase γ), NRF-1 (nuclear respiratory factor 1), PDK (pyruvate dehydrogenase
kinase), PDH (pyruvate dehydrogenase) and LDH (lactate dehydrogenase), RT-PCR was
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performed using the LightCycler TaqMan Master kit as described (Chen et al., 2008a). A
list of all primers used in this analysis is shown in Table 1.
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2.12 Statistical Analysis
Statistical analysis was performed using commercial software (GraphPad
PRISM®, GraphPad Prism, Inc., San Diego, CA), whereby a significant statistical
difference was defined as p < 0.05. Data were analyzed by Student‟s t-test or one-way
analysis of variance (ANOVA) followed by Newman-Keul‟s post hoc test to determine
significant difference between all groups compared to each other. Although there is no
set consensus in the scientific community on the correct choice of post hoc tests,
Newman-Keul‟s post hoc test was chosen because this test is designed to have more
power than other commonly used post hoc tests like the Tukey test. Given the nature of
this study using stem cells (that at any given time, were present in different stages of
differentiation) from human donors (who presented another variable in the study), a huge
inter-and intra variation in samples was expected. It was our understanding that the
additional power of the Newman-Keul‟s post hoc test would help to determine the
signiﬁcant diﬀerence between means.
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3. RESULTS
3.1

The Effect of Melatonin on ALP Activity in hAMSCs
To determine the treatment conditions that maximize melatonin-induced

mesenchymal stem cell differentiation into osteoblasts, a marker for osteoblast activity,
ALP was measured. As shown in Fig. 7, the addition of 50 nM melatonin to osteogenic
medium was only with effect (increased ALP) if it remained in contact with the cells for
the entire 21 d period or if it was added during the last 2 d of the 21 d treatment (Fig.
7A). There was no significant difference in ALP activity when the cells were exposed to
50 nM melatonin at the beginning of the OS+ 21 d treatment (stem cell growth medium
supplemented with 0.1µM dexamethasone, 10 µM β-glycerphosphate and 50 µM
ascorbate) (Fig. 7B). Because it was found that melatonin added during the last 2 d of the
21 d OS+ treatment induced ALP activity, the question was asked if time periods less
than 2 d were sufficient for melatonin to induce ALP activity. As shown in Fig. 7C, no
significant increase in ALP activity occurred in cells treated with melatonin for times less
than 2 d compared to control cells. To determine whether effects of melatonin on
inducing ALP activity was mediated through melatonin receptors, treatments were
performed in the presence of 4P-PDOT, a selective MT2 antagonist. As shown in Fig.
7D, the increase in melatonin-induced ALP activity at both 2 d and 21 d was blocked
with the addition of antagonist 4P-PDOT to OS+ medium.
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Figure 7: The Effect of Different Exposure Times on hAMSCs Differentiation into
Osteoblasts
To assess the impact of different periods of exposure on melatonin-induced osteoblast
differentiation, hAMSCs were plated at a density of 3 X 103 cells on a 12-well plate, and
incubated with OS+ medium in the presence or absence of 50 nM melatonin. All cells
were harvested on day 2 and the time points noted in the graph represent the length of
treatments. For example, 2 d in graph A means cells began melatonin treatment on day
19 of OS+ treatment. Control treatment in all graphs represents cells grown in OS+
medium for 21 days. ALP activity increased when melatonin was added during the last 2
d of the 21 d treatment (A), or if it remained in continuous contact with OS+ medium for
21 d (A, B). Exposure to melatonin for less than 2 d was without effect on inducing ALP
activity (C). These effects of melatonin were mediated through MT2 melatonin receptors
because the addition of 1µM 4P-PDOT (an MT2 melatonin receptor antagonist) to the
treatments containing both melatonin and OS+ medium blocked melatonin-induced
increases in ALP activity (D). Each bar represents mean ± SEM of 3-5 experiments
performed in duplicate. The data was analyzed by one-way ANOVA followed by
Newman-Keul‟s post hoc t-test where significance (*) was defined as p<0.05 compared
to vehicle (OS+) treated cells for 21 d.
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3.2

ALP Levels in hAMSCs Exposed to OS+ medium over Different Periods of
Time
To determine if pretreatment of hAMSCs with OS+ medium played a priming

role in increasing ALP activity in cells treated with 50 nM melatonin for 2 d, hAMSCs
were exposed to OS+ medium for varying lengths of time, before the melatonin was
added for 2 d. As depicted in Fig. 8, 2 d melatonin exposure was still able to
significantly increase ALP activity when hAMSCs were pre-exposed to OS+ medium for
17 d, however, the extent of ALP induction was less than hAMSCs pre-exposed to OS+
medium for 21 d.
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Figure 8: The Effect of Varying Pre-exposure to Osteogenic (OS+) Medium on 2 d
Melatonin Induction of ALP in Differentiated hAMSCS
To assess the effect of pretreatment or priming of hAMSCs with OS+ medium on ALP
activity, hAMSCs were plated at a density of 3 X 103 cells on a 12 well plate and exposed
to OS+ medium for varying times prior to the 2 d melatonin (50 nM) exposure. Dotted
lines represent total exposure to OS+ medium and solid lines represent melatonin
exposure (A). ALP activity is represented as a percentage of activity in control cells
(cells treated with OS+ medium in absence of melatonin). There was a significant
decrease in ALP activity in hAMSCs exposed to OS+ medium for less than 21 d (B).
Each bar represents mean ± SEM of 3 experiments performed in duplicate. The data was
analyzed by one-way ANOVA followed by Newman-Keul‟s post hoc t-test where
significance (*) was defined as p<0.05 compared to 21 d treatment.
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3.3

Saturation Binding Analysis on hAMSCs Exposed to Melatonin over Different
Time Periods
To determine if melatonin exposure affected the expression of melatonin binding

sites in hAMSCs, saturation binding analysis was performed using 2-[125I]-iodomelatonin
on cells exposed to 50 nM melatonin for indicated times in Study Design A and Study
Design B (Fig. 9). Other than the 10 d melatonin exposure in Study Design A, where
there was an increase in the 2-[125I]-iodomelatonin binding sites (3.86 fmol/mg protein)
as compared to control (0.17 fmol/mg protein), there was no significant difference in the
binding sites in any other treatment group vs. control, in both Study Design A and Study
Design B (Fig. 9). The relative expression of 2-[125I]-iodomelatonin binding in
differentiating hAMSCs was between 0.17-1.2 fmol/mg protein.
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Figure 9: Total 2-[125I]-iodomelatonin Binding Analysis on hAMSCs Treated with
Melatonin over Different Time Periods
To assess whether or not melatonin receptor expression fluctuated in response to different
treatment conditions, total melatonin receptor expression was measured using 2-[125I]iodomelatonin. hAMSCs were plated in 10 cm2 dishes and exposed to melatonin for
different times according to the Study Design A or B. 2-[125I]-iodomelatonin binding
sites were not found to be significantly different than control in both groups, except for
10 d melatonin exposure in Study Design A, where there was a significant increase in the
2-[125I]-iodomelatonin binding sites. Each bar represents mean ± SEM of 7-20
experiments performed in duplicate. The data was analyzed by one-way ANOVA
followed by Newman-Keul‟s post hoc t- test where significance (*) was defined as
p<0.05, when compared to vehicle-treated cells.
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3.4

Functional Analysis of Melatonin Receptors Expressed in Differentiating
hAMSCs Exposed to Melatonin over Different Time Periods
To access the function of melatonin receptors, cAMP assays were performed on

hAMSCs exposed to 50 nM melatonin for different times in Study Design A. Both MT1
and MT2 receptors are coupled mainly to Gi proteins that upon activation cause an
inhibition of adenylyl cyclase enzyme in the cells (Grant et al., 2009). This leads to a
decrease in second messenger cyclic AMP (cAMP) levels, PKA levels and CREB
phosphorylation (McNulty et al., 1994; Witt-Enderby et al., 2003). To measure the
decrease of cAMP with melatonin exposure, forskolin was added to the culture medium
to artificially increase the production of cAMP. The decrease in cAMP accumulation by
melatonin was measured as a function of forskolin response. hAMSCs in the control
group (not treated with melatonin) showed a decrease in forskolin induced cAMP
accumulation, suggesting sensitive melatonin receptors. Melatonin exposure for the last
2 d of a 21 d OS+ exposure resulted in melatonin receptor desensitization reflected by
attenuation in melatonin-mediated inhibition of forskolin-induced cAMP accumulation
(Fig. 10).
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Figure 10: Functional Analysis of Melatonin Receptors Expressed in hAMSCs
Exposed to Melatonin over Different Time Periods
To assess whether changes in melatonin receptor sensitivity occurred in response to
differential exposure to melatonin, cAMP accumulation assays were performed.
hAMSCs were plated in 12-well plates at a density of 3 X 103 cells/cm2 and exposed to
melatonin for 2, 10 or 21 d as described in Study Design A. Following exposure,
hAMSCs were assayed for total cAMP accumulation using commercial cAMP kits. As
shown, in vehicle-treated cells, 10 nM melatonin (a concentration known to decrease
cAMP accumulation) inhibited forskolin induced cAMP formation. Similarly, melatonin
inhibited cAMP formation in hAMSCs exposed to melatonin for 10 d according to Study
Design A. There was no significant inhibition of forskolin induced cAMP accumulation
when hAMSCs were exposed to melatonin for 2 d or 21 d in Study Design A. Each bar
represents mean ± SEM of 3-5 experiments performed in duplicate. The data was
analyzed by one-way ANOVA followed by Newman-Keul‟s post hoc t- test where
significance (*) was defined as p<0.05, when compared to forskolin induced cAMP
accumulation.
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3.5

The Effect of Melatonin Exposure on Calcium Deposition in Differentiating
hAMSCs
To determine the effect of differential melatonin exposure on calcium deposition

(a marker of bone mineralization) in hAMSCs, calcium deposition assays were carried
out using alizarin red staining in cells exposed to 50 nM melatonin. As shown, the
deposition of calcium was increased by about 900% only in hAMSCs exposed to
melatonin for entire 21 d (Fig. 11A). This melatonin mediated increase in calcium
deposition was blocked in the presence of MT2 melatonin receptor antagonist 4P-PDOT
(Fig. 11B).
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Figure 11: The Effect of Melatonin Exposures on Calcium Deposition in
Differentiating hAMSCs
To assess whether or not exposure to melatonin-induced calcium deposition in
differentiating hAMSCs, alizarin red staining assays were performed. Briefly, the
hAMSCs were plated in 24 well plates at a density of 3 X 103 cells/cm2 and exposed to
OS+ medium containing melatonin. Following the various melatonin exposures in the
21d period, osteogenesis quantitation was carried out using commercial kits, in which the
intensity of alizarin red staining was quantified. As shown, exposure to melatonin for 21
d induced calcium deposition by 900% compared to control (vehicle-treated cells) (A).
No increases in calcium deposition occurred at times of melatonin exposure less than 21

47

d in Study Designs A and B (A and B). The melatonin-mediated increase in calcium
deposition with 21 d exposure was blocked in the presence of MT2 antagonist 4P-PDOT
(1 µM) suggesting that these effects were occurring through MT2 melatonin receptors.
Each bar represents mean ± SEM of 3 experiments performed in duplicate. The data was
analyzed by one-way ANOVA followed by Newman-Keul‟s post hoc t- test where
significance (*) was defined as p<0.05 compared to vehicle-treated cells.
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3.6

Qualitative Assessment of Calcium Deposition in Differentiating hAMSCs
Exposed to Melatonin for 21 d
To qualitatively assess calcium deposition in hAMSCs exposed to melatonin for

21 d in presence of OS+ medium alizarin red staining was carried out. This was done to
visualize the calcium deposition under the microscope and determine if few or all cells
stain for calcium. The melatonin-treated cells depicted a higher level of staining
compared to the control treated cells. The staining was uniformly distributed among the
cells, demonstrating that melatonin-induced increase in calcium deposition was not
localized to few cells, depicting that mineralization was uniform and not a result of a few
cells laying down calcium in the matrix (Fig. 12).
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control
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Figure 12: Qualitative Assessment of Calcium Deposition in Differentiating
hAMSCs Exposed to Melatonin using Alizarin Red Staining
To assess the extent of calcium deposition by osteoblasts following a 21 d melatonin or
OS+ exposure, alizarin red staining analysis was performed. Briefly, the hAMSCs were
plated at a density of 3 X 103 cells/cm2 (upper panel) or 0.75 X 103 cells/cm2 in 10 cm2
dishes (lower panel) in 10cm2 dishes and exposed to OS+ medium in the absence or
presence of 50 nM melatonin for 21 d. After treatments, the cells were washed and
stained with 2% alizarin red solution. The red color indicates calcium deposition. As
shown in pictomicrographs of hAMSCs after staining, there was a marked increase in
staining in most of hAMSCs treated with melatonin compared to control treated cells.
(Magnification= 400 X)
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3.7

Proliferation of hAMSCs Treated with Melatonin for Different Times
To determine the effect of melatonin treatment on proliferation of hAMSCs, cell

proliferation assays were carried out on cells treated with 50 nM melatonin for the
indicated times according to Study Design A, as described in Materials and Methods. No
change in proliferation of hAMSCs occurred in presence of melatonin compared to
vehicle-treated cells (Fig. 13). The aim of this experiment was to determine if the changes
in melatonin induced changes in the cells were due to changes in their proliferation.
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Figure 13: Proliferation of hAMSCs Treated with Melatonin for Different Times
To assess whether melatonin exposures for 2, 10 or 21 d using Study Design A described
in Materials and Methods, affected the proliferation of the differentiating hAMSCs,
proliferation assays were conducted. Briefly, hAMSCs were plated in 12-well plates at a
density of 3 X 103 cells/cm2 and exposed to melatonin for 2, 10 or 21 d in presence of
OS+ medium. The cell proliferation was determined using commercial CellTiter
96AQueous One Solution Cell Proliferation Assay Kit . As shown, there was no significant
difference in proliferation of cells treated with 50 nM melatonin for indicated times
compared with the control treated cells. Each bar represents mean ± SEM of 3
experiments performed in duplicate. The data was analyzed by one-way ANOVA
followed by Newman-Keul‟s post hoc t-test where significance (*) was defined as
p<0.05, compared to vehicle-treated cells.
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3.8

The Effect of a 21 d Melatonin Exposure on Mitochondrial Gene Expression in
Differentiating hAMSCs
Many studies have reported on melatonin‟s action on mitochondria and its

functions (Reiter et al., 2001). Studies have shown that mitochondrial function is related
to the differentiation process (Duguez et al., 2002; Cho et al., 2006; Chen et al., 2008a).
To assess whether or not changes in mitochondrial biogenesis occurred as a result of the
21 d melatonin exposure, real time RT-PCR studies were carried out. Specifically, the
effect of melatonin on the mitochondrial genes, mitochondrial transcription factor A
(mtTFA), PPAR coactivator-1 α (PGC-1α), DNA polymerase γ (Pol γ) and nuclear
respiratory factor 1 (NRF-1) were examined. No difference was found in the expression
of these genes in cells treated with 50 nM melatonin for 21 d compared to the vehicletreated cells (Fig. 14).
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Figure 14: The Effect of a 21 d Melatonin Exposure on Mitochondrial Gene
Expression in Differentiating hAMSCs
To assess whether or not changes in mitochondrial biogenesis within differentiating
hAMSCs correlated with melatonin-mediated osteoblast differentiation, real time RTPCR analysis was carried out. The cells were cultured in 10cm2 dishes in OS+ medium
alone (control) or in presence of 50 nM melatonin (Mel) for 21 d. As described in
Materials and Methods, cells were lifted in TRIZOL, total RNA was isolated and reverse
transcribed into cDNA. Real-time RT-PCR analysis was carried out using primers
specific for mtTFA, PGC-1α and Pol γ NRF-1. The primer sequences are given in Table
1. As shown, there was no significant difference in mRNA levels of mitochondrial
biogenesis genes in hAMSCs treated with 50 nM melatonin for 21 d compared to vehicletreated cells. ΔCt values were determined by normalization to GAPDH to control for
variation in cDNA levels between samples. Lower ΔCt values indicate higher gene
abundance. The relative fold changes over control are denoted as numbers in the bars.
Each bar represents mean ± SEM of 4 experiments performed in duplicate. The data was
analyzed by Student‟s t-test where (*) was defined as p<0.05, when compared to control.
Abbreviations: mtTFA (mitochondrial transcription factor A), PGC-1α (PPAR
coactivator-1 α) and Pol γ (DNA polymerase γ) and NRF-1 (nuclear respiratory factor).
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3.9

The Effect of a 21 d Melatonin Exposure on Genes Involved in Anaerobic
Metabolism
It has been suggested in a previous study that there is a “metabolic shift” which

reprograms the bioenergetic properties of hAMSCs from anaerobic glycolysis to
mitochondrial respiration to meet the higher energy demand of differentiated osteoblasts
(Chen et al., 2008a). To assess whether or not changes in anaerobic metabolism occurs as
a result of the 21 d melatonin exposure, real time RT-PCR studies were carried out.
Specifically, the effect of melatonin on genes involved in anaerobic metabolism, pyruvate
dehydrogenase kinase (PDK), pyruvate dehydrogenase (PDH) and lactate dehydrogenase
(LDH ) were examined. No difference was found in the expression of these genes in cells
treated with 50 nM melatonin for 21 d compared to the vehicle-treated cells (Fig. 15).
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Figure 15: The Effect of a 21 d Melatonin Exposure on Genes Involved in
Anaerobic Metabolism
To assess whether or not changes in anaerobic metabolism within differentiating
hAMSCs correlated with melatonin-mediated osteoblast differentiation, real time RTPCR analysis was carried out. The cells were cultured in 10cm2 dishes in OS+ medium
alone (control) or in presence of 50 nM melatonin (mel) for 21 d. As described in
Materials and Methods, cells were lifted in TRIZOL, total RNA was isolated and reverse
transcribed into cDNA. Real-time RT-PCR analysis was carried out using primers
specific for PDK, PDH and LDH. The primer sequences are given in Table 1. As
shown, there was no significant difference in mRNA levels of genes involved in
anaerobic metabolism in hAMSCs treated with 50 nM melatonin for 21d compared to
control treated cells. ΔCt values were determined by normalization to GAPDH to control
for variation in cDNA levels between samples. Lower ΔCt values indicate higher gene
abundance. The relative fold changes over control are denoted as numbers in the bars.
Each bar represents mean ± SEM of 4 experiments performed in duplicate. The data was
analyzed by Student‟s t-test where (*) was defined as p<0.05, when compared to control.
Abbreviations: PDK (pyruvate dehydrogenase kinase), PDH (pyruvate dehydrogenase),
LDH (lactate dehydrogenase).
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3.10 The Effect of Various Melatonin Exposures on Expression of Genes Involved
in Osteogenesis
To determine the effect of melatonin treatment on expression of osteogenic genes,
real time RT-PCR studies were carried out. This was done so as to provide possible
mechanisms underlying melatonin‟s induction of osteoblasts from hAMSCs and to
determine the specific genes that were affected by melatonin. Treatment with 50 nM
melatonin per Study Design A significantly increased the expression of the early
osteogenic gene, RUNX-2. The exposure of melatonin for the last 2 d in the 21 d
exposure increased the expression of RUNX-2 gene 38.14 times compared to control and
persisted in exposures that lasted for 5, 10, 14 and even 21 d. These increases in
expression of RUNX-2 were blocked with the addition of 1µM 4P-PDOT to the medium,
suggesting the involvement of MT2 melatonin receptors (Fig. 16A).
With respect to intermediate and late osteogenic gene expression, the expression
of gene OC in melatonin-treated cells was not significantly increased over vehicle-treated
cells. However, the levels of OC mRNA expression were significantly decreased in the
presence of 4P-PDOT. The expression of osteocalcin was increased from 2.60-4.68 folds
over control (1.00) and this increase was reversed by the addition of 4P-PDOT (Fig.
16B). The expression of BMP-2 in hAMSCs treated with melatonin for 2, 5, 10 and 14 d,
but not 21 d, showed a 2.1-3.8 fold increase over vehicle-treated cells. This increase in
the expression of the mRNA was inhibited by the addition of 4P-PDOT (1µM) to the
medium (Fig. 16C). Finally, the expression of BMP-6 and ALP mRNA was not
statistically different in cells exposed to melatonin compared to vehicle-treated cells and
the addition of 4P-PDOT was without effect on either gene (figs.16D and E).
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Figure 16: The Effect of Melatonin Exposure on the Expression of Genes Involved
in Osteogenesis
To assess whether or not changes in genes involved in osteogenesis within differentiating
hAMSCs were regulated by melatonin, real time RT-PCR analysis was carried out. The
cells were cultured in 10cm2 dishes in OS+ medium alone (control) or in presence of 50
nM melatonin (mel) for 21 d. As described in Materials and Methods, cells were lifted in
TRIZOL, total RNA was isolated and reverse transcribed into cDNA. Real-time RT-PCR
analysis was carried out using primers specific for RUNX-2, OC, BMP-2, BMP-6, and
ALP. The primer sequences are given in Table 1. As shown, the expression of early
osteogenic gene- RUNX-2 was significantly increased in cells treated with melatonin
compared to vehicle-treated cells and this increase was blocked by 1 µM 4P-PDOT (A).
The expression of gene OC in melatonin-treated cells was not significantly increased over
vehicle-treated cells. However, the levels of OC mRNA expression were significantly
decreased in the presence of 4P-PDOT (B). Melatonin exposure during the last 2, 5, 10
and 14 d of the 21 d OS+ exposure increased mRNA expression of BMP-2 compared to
vehicle-treated cells. No increase in BMP-2 expression occurred if the melatoninexposure was constant and lasted for full 21 d. The addition of 4P-PDOT blocked
melatonin‟s effects (C). No melatonin-mediated or 4P-PDOT- mediated changes
occurred in mRNA expression of BMP-6 (D) or ALP (E), compared to vehicle-treated
cells. ΔCt values were determined by normalization to GAPDH to control for variation in
cDNA levels between samples. Lower ΔCt values indicate higher gene abundance. The
relative fold changes over control are denoted as numbers in the bars. Each bar represents
mean ± SEM of 3-10 experiments. The data was analyzed by one-way ANOVA followed
by Newman-Keul‟s post hoc t- test. a p < 0.05 compared to control, b p < 0.05 compared
to melatonin-treated group for the same treatment time. Abbreviations: RUNX-2 (runt
related transcription factor-2), OC (osteocalcin), BMP-2 (bone morphogenetic protein-2),
BMP-6 (bone morphogenetic protein-6), ALP (alkaline phosphatase).
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4. DISCUSSION
Various studies have reported that melatonin can have a protective effect on bone
by stimulating osteogenesis and preventing its degradation (Cardinali et al., 2003;
Fjelldal et al., 2004; Turgut et al., 2005; Witt-Enderby et al., 2006) through a variety of
mechanisms. Some of the mechanisms include- 1) inhibiting bone resorption through its
effect on osteoclasts, RANKL (NF-κB ligand) and OPG (osteoprotegerin), 2) scavenging
free radicals generated by osteoclasts and bone metabolism processes, and 3) stimulating
the proliferation and differentiation of osteoblasts (Roth et al., 1999; Koyama et al., 2002;
Suzuki and Hattori, 2002; Radio et al., 2006; Witt-Enderby et al., 2006; Suzuki et al.,
2008b).
Melatonin has previously been reported to stimulate the differentiation of
hAMSCs into osteoblasts when the cells were exposed to 50 nM melatonin for 10 d in
presence of osteogenic medium (OS+ medium, described previously) (Radio et al., 2006).
The aim of this study was to determine the critical time periods of melatonin exposure
that are required for stimulating the differentiation of hAMSCs into osteoblasts and to
determine the various osteogenic genes involved in the process. Mineralization, an
essential component of bone differentiation process, takes place between 14 and 21 d in
culture (Matsumoto et al., 1991; Eijken et al., 2005). The hAMSCs were, therefore,
cultured in the OS+ medium for 21 d to induce their differentiation into osteoblasts
whereby melatonin was added to the medium at different time points and for different
time periods during the course of the culture. The treatment paradigm was divided into
two study designs based on when melatonin was added to the OS+ medium over the
period of the 21 d culture. As depicted in Fig. 5, Study Design A consisted of cells that
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were exposed to 50 nM melatonin during the latter part of the 21 d culture. Study Design
B consisted of cells that were exposed to 50 nM melatonin at the beginning of the 21 d
culture. These two study designs were performed as such, so as to determine when
melatonin exerts its maximal effect in stimulating osteogenesis- at a later stage of
osteoblastic differentiation (Study Design A) or the initial phase of differentiation (Study
Design B). These study designs and treatment groups would also indicate if short term or
longer melatonin exposure was favorable to osteogenesis.
ALP activity is a used as a marker to assess osteoblast differentiation and its
activity is reported to increase as the differentiation progresses (van Straalen et al., 1991;
Bruder et al., 1997; Christenson, 1997; Jaiswal et al., 1997; Pittenger et al., 1999). In the
present study it was observed that a continuous melatonin exposure for 21 d in hAMSCs
increased their differentiation into osteoblasts as was measured by an increase in ALP
activity, compared to the control group of cells that was devoid of melatonin exposure
(Fig. 7). Continuous exposure to parathyroid hormone, PTH, is known to cause an
increase bone resorption resulting in bone loss through osteoclast differentiation and
increases in the RANKL: OPG ratio. An intermittent exposure, though, causes
stimulation of bone formation (Hock and Gera, 1992; Locklin et al., 2003). These data
suggest that the duration of exposure, continuous or intermittent, can modulate hormone
effects on bone metabolism. Results from the various treatment groups in our study
suggest that unlike the parathyroid hormone, melatonin needs to be administered
continuously to have a positive effect on bone formation. This may hold significance invivo as melatonin may provide a therapy for osteoporosis that is more convenient than
PTH.
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Often, early biochemical events associated with the differentiation process trigger
a signaling cascade culminating with transcription regulatory changes leading to
differentiation of cells. For example, in keratinocytes, early exposure to calcium for 3-6
d commits most cells in culture to differentiation (Dotto, 1999). Notch, a protein
involved in the regulation of osteoblast and osteoclast homeostasis (Tezuka et al., 2002;
Sciaudone et al., 2003; Zamurovic et al., 2004; Engin et al., 2008) is also involved in
differentiation of embryonic stem cells to neural cells where it directs a domino effect.
Once it is switched on in a small group of cells, it sets off a wave of Notch activation in
neighboring cells, directing them all to become cells of the nervous system (Lowell et al.,
2006). To investigate whether melatonin could have a similar effect in triggering the
process of differentiation, ALP activity was measured after melatonin was administered
to the cells in the early stages of differentiation process and then removed from the
medium (Study Design B- Fig. 7B). These results demonstrate that melatonin did not
have an effect on ALP activity when added to hAMSCs and then removed, suggesting
that melatonin does not have a domino effect on the differentiation processes.
Interestingly, a significant increase in ALP activity was observed when melatonin
was added to the medium for 2 d towards the end of the 21 d in OS+ culture, compared to
the cells treated only with OS+ medium for 21 d (Study Design A- Fig. 7A). However,
no significant affect on the ALP activity in cells treated with melatonin for 5, 10 or 14 d
towards the end of the 21 d culture in OS+ medium compared to control cells. These
results were similar to the study reported by Roth et al (1999) which suggested that
MC3T3 cells must first undergo differentiation before they become responsive to
melatonin. Although our 21 d continuous melatonin treatment does not support this
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hypothesis, it is possible that the hAMSCs were in an advanced stage of differentiation
due to the osteogenic medium (OS+) effects on the intracellular machinery required for
melatonin to have its effect (melatonin was added on the 19th d of culture in osteogenic
medium). These results underscore the importance of both timing and duration of
melatonin on inducing osteoblast differentiation from hAMSCs.
The osteoblast lineage begins with multi-potent mesenchymal stem cells, located
in the bone marrow. Once they are committed to a lineage (i.e.,. osteoblasts, adipocytes
or chondrocytes), the stem cells begin to divide to give rise to another stem cell and an
immature osteo-progenitor cell. This process is called self renewal. The immature osteoproginetor cell matures and undergoes intensive proliferation and further differentiation
to form pre-osteoblasts. Differentiation of pre-osteoblasts gives birth to mature
osteoblasts that have limited replicative potential. The terminal stage of this
differentiation process is an osteocyte which lays new bone (Thomas and Kansara, 2006).
From our study it can be hypothesized that there is an increase in differentiation
of hAMSCs into osteoblasts (as measured by an increase in ALP activity) when the cells
were exposed to melatonin either before the differentiation is initiated (21 d), or at a later
stage of differentiation, when the machinery required for melatonin-induced
differentiation was induced by a 19 d pre-exposure to osteogenic medium. Possibly,
melatonin does not have an effect on the intermediate stages of hAMSC differentiation as
measured by an increase in ALP activity. The intermediate stages of differentiation of
stem cells are marked by a sharp increase in proliferation In our system we see no
change in the proliferation of stem cells following melatonin exposure (Fig. 13),
suggesting that melatonin acts to modulate different stages of differentiation rather than
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proliferation. These results are consistent with cellular differentiation as a whole where
high stages of differentiation are most often associated with low levels of proliferation.
The increase in ALP activity was not observed, when melatonin was added for less than 2
d towards the end of the 21 d culture. These findings suggest that the time of melatonin
exposure was not long enough on the MT2 melatonin receptor to impact on downstream
signaling processes (Fig. 7B). As mentioned before, exposure and then removal of
melatonin from the medium (Study Design B), resulted in no increase in ALP activity,
suggesting that continuous melatonin treatment is necessary for the increase in
differentiation process.
This biphasic response to melatonin could also be a result of the cyclic expression
of ALP throughout the 21 d treatment. In primary mouse calvarial cells and embryonic
stem cells, ALP expression increases first and then decreases in cells treated with
osteogenic medium (zur Nieden et al., 2003; Siddappa et al., 2009). In a recent study
using rat mesenchymal stem cells cultured in osteogenic medium, it was shown that both
ALP activity and its mRNA levels were decreased in the early (0-8 d) and late stages (>
16 d) of differentiation, compared to the intermediate stage (8-16 d) (Nakamura et al.,
2009). Although not tested in this study, it can be speculated that during the intermediate
stage, levels of ALP expression induced by the osteogenic medium alone were maximal
such that melatonin was not able to increase them further. More experiments using
osteogenic medium alone are needed to investigate the reason for this response and to
determine if there are cyclic changes in the ALP expression levels as the differentiation
progresses.
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Studies were carried also out to determine how the level of pre-differentiation of
cells induced by the osteogenic medium alone affected the 2 d melatonin increase in ALP
activity (Fig. 8). These experiments were performed by varying the time period of
osteogenic medium exposure before adding melatonin for 2 d. The data show that there
is a critical time of osteogenic pre-exposure required (i.e.,. 19 d) before a 2 d melatonin
can induce its highest effect on ALP activity. These findings corroborate our previous
hypothesis that melatonin can increase the ALP activity when cells were exposed to it in
later stages but not in intermediate stages of differentiation.
To further support the hypothesis that melatonin, added in combination with
osteogenic medium enhances hAMSC differentiation into osteoblasts, calcium deposition
was measured in addition to ALP activity. These data show that melatonin-induced
increases in ALP activity were associated with increases in calcium deposition (figs. 11A
and B). Calcium deposition as judged by alizarin red staining was distributed evenly
through the culture and not localized to a few cells (Fig. 12). An increase in calcium
deposition or mineralization is one of the most important markers of bone formation
(Matsumoto et al., 1991; Jaiswal et al., 2000; Bancroft et al., 2002; Titorencu et al.,
2007). Thus, in hAMSCs, a 21 d continuous melatonin exposure enhances cellular
differentiation. Although the results show that 2 d melatonin exposure towards the end of
the 21 d OS+ exposure period also causes an increase in ALP activity, this did not
translate to enhancement in calcium deposition (Fig. 11A). Calcium deposition is one of
the final markers of bone formation, and as explained further in the following paragraphs,
it may be a better marker to study bone formation than ALP activity. The increase of
melatonin-induced ALP activity and calcium deposition were inhibited in the presence of
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the MT2 melatonin receptor antagonist 4P-PDOT, suggesting that MT2 melatonin
receptors were involved in this process (Fig. 7D and 11C).
Melatonin receptors mainly couple to Gi proteins and, upon stimulation they
inhibit intracellular cyclic AMP accumulation (Witt-Enderby and Dubocovich, 1996; von
Gall et al., 2002; Sethi et al., 2008). As shown in Fig. 10, hAMSCs first treated with
melatonin for 2 d or 21 d (Study Design A) and then re-challenged with melatonin (20
min) did not result in an inhibition of forskolin induced cAMP accumulation, indicating
desensitized melatonin receptors. To determine whether or not melatonin binding sites
were modified following hAMSCs differentiation into an osteoblast, 2-[125I]iodomelatonin saturation analysis was performed. Results indicate that differentiating
hAMSCs express low levels melatonin receptor binding sites (≤ 1.5 fmol/mg protein),
however they were not significantly modulated by the different melatonin exposures,
except for the 10 d melatonin exposure. Exposure to melatonin for 10 d towards the end
of the 21 d treatment demonstrated an increase in 2-[125I]-iodomelatonin binding. This
increase in binding could reflect changes in the MT2 – G protein coupling, since 2-[125I]iodomelatonin is an agonist radioligand and its binding to melatonin receptors could be
modulated by the state of MT2 receptor/ G-protein coupling. These data indicate that the
functional sensitivity of MT2 melatonin receptors expressed in differentiating hAMSCs
may underlie the melatonin-induced hAMSCs differentiation into osteoblasts and
corroborates previous results shown by Radio et al (2006), where it was reported that
melatonin-mediated decreases in cAMP were attenuated at the peak of hAMSCs
differentiation into osteoblasts. It was also shown in this study that the loss of coupling
to cAMP-dependent pathways was accompanied by a gain in MAPK function through β-
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arrestin scaffolding to MT2 receptor in these same cells (Radio et al., 2006). Similar
mechanisms have been reported for PTH (parathyroid) receptors expressed in HEK cells,
where ERK 1/2 activation occurred through both a cAMP dependent pathway as well as a
β-arrestin dependent pathway that depended upon the duration of PTH exposure (GestyPalmer et al., 2006).
There have been many studies reported on melatonin‟s action on mitochondria
and its functions. Mitochondria generate most of the cell's supply of adenosine
triphosphate (ATP) through the electron transport chain. The electron transport chain
constantly leaks a small amount of electrons that cause oxidative damage to DNA,
proteins, and lipids through the production of ROS (reactive oxygen species) (Adam-Vizi
and Chinopoulos, 2006). Melatonin is a powerful antioxidant and free radical scavenger
that directly scavenges ROS (Reiter et al., 2001). Melatonin‟s effect on the mitochondria
include increased membrane fluidity, more efficient activity of the electron transport
chain, reduced oxidative stress and increased mitochondrial membrane potential (AcunaCastroviejo et al., 2007). Studies have shown that mitochondrial function is related to the
differentiation process (Duguez et al., 2002; Cho et al., 2006; Chen et al., 2008a). As
stem cells lose pluripotency and commit to a lineage, the expression of mtDNA
(mitochondrial DNA) transcription and replication factors is upregulated and the number
of mitochondria and mtDNA copies/ cell increases (Facucho-Oliveira and St John, 2009).
A study using human mesenchymal stem cells has reported that an increase in
differentiation of the cells into osteoblasts caused an increase in the mRNA levels of
genes involved in mitochondrial biogenesis- mtTFA, Pol-γ, and PGC-1α (Chen et al.,
2008a) . There was also a concurrent decrease in lactate production rate, glycolytic
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enzyme PDK and increase in PDH, the enzyme that is responsible for converting
pyruvate into acetyl CoA to enter the tricarboxylic acid cycle and aerobic metabolism. It
was proposed that on induction of differentiation, there is a “metabolic shift” which
reprograms the bioenergetic properties of hAMSCs from anaerobic glycolysis to
mitochondrial respiration to meet the higher energy demand of differentiated osteoblasts
(Chen et al., 2008a). In our study, the levels of the genes involved in mitochondrial
biogenesis and glycolysis did not change with a 21 d melatonin treatment (Fig. 14 and
15). While this does not indicate whether melatonin treatment alters the mitochondrial
function or if it induces the production of antioxidant enzymes in these cells, this was the
first study looking at the effect of melatonin on mitochondrial biogenesis in
differentiating hAMSCs. Perhaps, the levels of the genes involved in mitochondrial
biogenesis plateaued during hAMSC differentiation with osteogenic medium (OS+) alone
as shown in another study (Chen et al., 2008a), such that no further effect of melatonin
could be observed. Also, it is possible that melatonin does participate in the “metabolic
shift” of these cells from anaerobic glycolysis to mitochondrial respiration because there
was no change in the mRNA expression levels of genes involved in cellular metabolism
like PDH and PDK.
The differentiation of osteoblasts from hAMSCs is controlled by a variety of
osteogenic genes. The most important of them is RUNX-2, which is a master regulator of
many other osteogenic genes (Ducy et al., 1997). RUNX-2 can directly stimulate
transcription of OC by binding to specific enhancer regions of the gene (Kim et al.,
2007). Osteocalcin and other proteins allow osteoblasts to mineralize collagen I-rich
matrix to form bone (Kwok et al., 2009). A mutation of this gene in mice leads to a
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skeletal system that is completely devoid of ossification (Komori et al., 1997). Bone
morphogenetic proteins (BMPs) are a part of the TGF-β superfamily of ligands. As
shown in Fig. 3, BMP-2 binds to a TGF- β type II transmembrane receptor. The type II
receptor, a serine/ threonine receptor kinase, phosphorylates the TGF- β type I receptor
and forms a complex. These complex results in phosphorylation of downstream
regulators called R-smads which complex with Co-smads. This complex translocates into
the nucleus to regulate the transcription of target osteogenic genes (e.g. RUNX-2) (Lian et
al., 2006; Huang et al., 2007). As shown in Fig. 3, another transcription factor called The
gene, osterix is activated downstream of RUNX-2, which is indispensable for bone
development (Matsubara et al., 2008). In osterix null mice, an absence of bone formation
occurs at the embryonic stage (Nakashima et al., 2002). BMP-2 treatment has been
reported to cause an increase in expression of RUNX-2 mRNA (Lee et al., 2000). BMP-2
can also signal in a Smad-independent manner and can activate the MAPK pathway
which can in turn regulate RUNX-2 expression in osteogenic cells (Lai and Cheng, 2002;
Xiao et al., 2002; Huang et al., 2007).

BMP-2 also controls osteogenesis through Wnt/

beta-catenin signaling (Fig. 3) (Rawadi et al., 2003).
Real time RT-PCR studies on hAMSCs treated with melatonin or melatonin and
4P-PDOT demonstrated that RUNX-2 mRNA expression was increased by melatonin
(Fig. 16A). Although not statistically significant, we also observed a consistent increase
in the mRNA expression levels of BMP-2 and OC with the treatment of melatonin (figs.
16B and C) that was blocked by the use of 4-P-PDOT at all time periods studied,
indicating that MT2 receptors were involved in the process. Unexpectedly, the mRNA

68

expression of ALP did not change on melatonin treatment. The possible reasons are
outlined in the following paragraph.
Based on the results, we suggest that melatonin, acting through MT2 melatonin
receptors, increases the differentiation of hAMSCs as measured by an increase in ALP
activity and through an increase in mRNA expression of the osteogenic genes RUNX-2,
BMP-2 and OC. From the results of this study, it is hypothesized that there are at least 2
different signal transduction pathways involved in melatonin-mediated differentiation of
hAMSCs into osteoblasts, as depicted in Fig. 17. The pathway (marked B in schematic)
shows that MAPK activity is increased through MT2 receptor/ β-arrestin scaffold
formation and this acts to increase ALP activity. MT2R/ β-arrestin scaffolds only form
following MT2 receptor desensitization by chronic melatonin exposure (Radio et al.,
2006). Though not modulated via transcriptional events, the increase in ALP activity
could be due to translational or posttranslational processing to increase ALP activity.
The second pathway (denoted A in schematic) hypothesized by this study also
involves the MAPK pathway but involves sensitive MT2 receptors, that is, melatonin
receptors capable of inhibiting forskolin induced cAMP formation when activated by
melatonin. It is suggested that the activation of Gi protein due to binding of melatonin to
MT2 receptors inhibits adenylyl cyclase and PKA and dephosphorylation of raf-1, which
causes activation of MEK(1/2) and ERK(1/2). Melatonin has been previously reported to
increase phosphorylation of these proteins through an inhibition of PKA in MT1-CHO
cells (Witt-Enderby et al., 2000). PKA acts to inhibit Raf-1 or Raf-B that are activators
of MEK (1/2) (Burgering and Bos, 1995). Activation in ERK (1/2) can directly
phosphorylate sites on the RUNX-2 transcription factor causing an increase in
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transcription of other osteogenic genes (Xiao et al., 2000; Franceschi et al., 2007). OC
and BMP-2 are genes whose expression is controlled by RUNX-2. After translation, the
BMP-2 protein can act as an autocrine/ paracrine factor and stimulate transmembrane
TGF-β receptors and activate the MAPK pathway (Derynck and Zhang, 2003). BMP-2
has been reported to activate various matrix metalloproteinases (MMP) in some studies
(Nakashima and Tamura, 2006; Tang, 2008), and the inhibition of MMP caused a
decrease in melatonin-induced increase in ALP activity in hAMSCs (Radio et al., 2006).
There are reasons why two separate pathways are hypothesized for the effect of
melatonin on differentiation of hAMSCs. The increase of ALP activity following 2 d or
21 d melatonin treatment (Study Design A) was not correlated with the increase in
mRNA expression of osteogenic genes that were increased at all time periods of
melatonin exposure. This, in itself, may not be substantial evidence for separate
pathways because gene expression precedes protein expression in a cell, however, the
complete lack of the trend (observed with ALP activity) points towards a different
pathway. Secondly, the mRNA levels of the osteogenic genes RUNX-2, BMP-2 and OC
were increased at time periods of melatonin treatment when the melatonin receptors were
sensitive as well as desensitized (with respect to a decrease in forskolin induced cAMP
activity), whereas the ALP activity was increased only with those time periods of
melatonin exposure that caused the melatonin receptors to desensitize with respect to
cAMP signaling. Lastly, the expression of ALP mRNA did not change with melatonin
treatment, but its upstream regulators (RUNX-2 and BMP-2) and downstream markers
(ALP activity) were increased compared to the control cells following 2 d and 21 d time
exposures. From this, it can be hypothesized that there is a missing connection between

70

the upstream and downstream markers and this is possibly due to their signaling via
different pathways. As previously shown (Radio et al., 2006), the increase in ALP
activity is dependent upon MEK and ERK1/2 activation as inhibition of MEK1/2 by a
MEK inhibitor blocked completely the melatonin-induced increases in ALP activity in
hAMSCs (Radio et al., 2006).
It is hypothesized that co-modulation of MAPK through different pathways ensures
appropriate intracellular signals to enhance hAMSC differentiation. Because the
endogenous regulation of melatonin biosysthesis, both systemic and in the bone marrow,
is chronobiotic in nature with high levels of melatonin occurring during the period of
darkness which persist for at least 8 h each night, then differential modulation of
melatonin receptor sensitivity states within the bone may serve to direct appropriate
intracellular pathways to maintain healthy bone. In this study, an increase calcium
deposition, which is a final result of osteogenesis did not correlate with an increase in
ALP activity. The increase in ALP activity also did not correlate with the expression of
various osteogenic genes. From this, it is suggested that ALP activity may not be the best
indicator for differentiation. Mineralization may be a better marker as it can provide an
indication of final stages of differentiation and is less likely to be influenced by various
factors to which a protein like ALP could be susceptible.
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Figure 17: Proposed Mechanism of Melatonin’s Action within a Differentiating
Human Adult Mesenchymal Stem Cell into an Osteoblast
In the present study it is proposed that melatonin could affect the differentiation of
hAMSCs into osteoblasts through two pathways denoted as A and B in the schematic. As
shown in pathway A, melatonin, through an activation of MT2Rs leads to an inhibition of
adenylyl cyclase, decreases in cAMP and decreases in PKA which then promotes the
activation of MAPK (ERK1/2, p-38 or JNK). As shown in pathway B, upon chronic
melatonin exposure, MT2Rs desensitize and form scaffolds with βarrestins/Gi/MEK/ERK1/2) leading to ALP activation in the cytoplasm. Both pathways
converge on MAPK (ERK1/2, p-38 or JNK), which then increases the expression of the
transcription factor RUNX-2 in the nucleus. The activation of RUNX-2 increases the
mRNA expression of osteogenic genes OC and BMP-2. The BMP-2 protein upon
translation can act as an autocrine/ paracrine factor to also activate MAPK via Smadindependent signaling via pathway A. BMP-2 may also contribute to the activation of
pathway B by activating MMPs resulting in HB-EGF shedding and activation of EGFR.
[Abbreviations: EGFR (epidermal growth factor receptor), HB (heparin bound), EGF
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(epidermal growth factor), MEK1/2 (MAP-ERK kinase), ERK1/2 (extracellular signalregulated kinase), MMP (matrix metalloproteinase), ALP (alkaline phosphatase), RUNX2 (Runt-related transcription factor 2), BMP-2 (bone morphogenetic protein-2), JNK (cJun N-terminal kinases).
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5. CONCLUSION
The findings from this study demonstrate that melatonin enhances bone formation
through the enhancement of osteoblast differentiation in a clinically relevant human adult
mesenchymal stem cell line. Various treatment times of melatonin exposure caused
variable changes in different markers of osteogenesis and a continuous (21 d) treatment
resulted in an increase in calcium deposition. These findings suggest that a continuous
melatonin treatment might be most effective at preventing or treating osteoporosis.
These results also reinforce the prominent role that MT2 melatonin receptors play in bone
stem cell differentiation and through the mitogen activated protein kinase cascade. As no
major side effects have been reported with melatonin administration, drugs targeted at
MT2 melatonin receptors to modulate its sensitivity states may provide novel, safe,
alternative therapies to treat osteoporosis. Furthermore, seeing that the risk of
osteoporosis increases in women with age and for nightshift workers (two conditions that
result in low circulating levels of melatonin), perhaps directed therapies to replenish night
time melatonin levels back to normal could prevent against bone loss.
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Chapter 2
A Study on C-Terminal Domains of MT1 AND MT2 Melatonin Receptors
6. INTRODUCTION
Melatonin is released from the pineal gland during the hours of darkness.
Melatonin‟s levels in the body are decreased in a variety of diseases, e.g. breast, prostate,
lung and colorectal cancer, osteoporosis, insomnia, seasonal affective disorder and
Alziemer‟s disease (Ekmekcioglu, 2006). Melatonin often exerts its effects via G-protein
coupled melatonin receptors, MT1 and MT2 (Reppert et al., 1994; Reppert et al., 1995),
however, it can modulate quinone reductase-2 enzyme activity via a melatonin binding
site, MT3 (Tan DX et al., 2007). An orphan receptor (GPR50) was also identified, which
has a 45% homology to the melatonin receptors (Reppert et al., 1996; Drew et al., 1998).
MT1 and MT2 receptors mainly couple to pertussis toxin-sensitive Gi proteins
(Carlson et al., 1989; Brydon et al., 1999), and inhibit intracellular cAMP accumulation
followed by a decline in PKA activity and CREB (cAMP regulatory element-binding
protein) phosphorylation (Witt-Enderby and Dubocovich, 1996; von Gall et al., 2002;
Dubocovich et al., 2003). Similar to other GPCRs, the MT1 and MT2 have seven
transmembrane (TM) domains, connected by three extracellular and three intracellular
loops, and consist of 350 and 362 amino acids respectively (Mazna et al., 2004;
Hardeland, 2009). Homology models of the melatonin receptors are based on the crystal
structure of rhodopsin (Palczewski et al., 2000). The extracellular loops may be involved
in ligand recognition, and the intracellular loops may participate in G-protein binding
(Drew et al., 1998; Mazna et al., 2005). Based on the knowledge of the rhodopsin
structure, this study sought to understand the function and regulation of melatonin
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receptors through construction of two mutants in the C-terminal tails of the MT1 and MT2
receptors (Fig.18).
In the first mutation, a cysteine residue in the C-terminal tail was mutated to
alanine (MT1C7.72A and MT2C7.77A). This site is essential for the G-protein binding of
the rhodopsin receptor. The cytoplasmic surface of rhodopsin consists of four
intracellular loops. The first, second and third intracellular loops connect adjacent
transmembrane helices. The fourth intracellular loop is formed by attachment of
palmitoyl groups to two cysteine residues (Cys 322, and Cys 323) in the C-terminal
region, and inserting it into the lipid bilayer (Ovchinnikov Yu et al., 1988; Moench et al.,
1994). It has been suggested that the fourth intracellular loop interacts directly with Gt,
and plays a role in the regulation of Gtβγ subunit (Ernst et al., 2000). Palmitoylation has
been reported for other GPCRs like human luteinizing hormone receptor, where the
palmitoylation state of the receptor governs the accessibility of the receptor to betaarrestins to regulate receptor internalization (Munshi et al., 2001). Mono-, bis- or trispalmitoylation of the cysteine residues of the C-tail also occurs in β-adrenergic receptors,
α-adrenergic receptors, muscarine acetylcholine receptors, vasopressin receptors,
dopamine receptors, bradykinin receptors and many others (O'Dowd et al., 1989a;
Kennedy and Limbird, 1994; Qanbar and Bouvier, 2003). Palmitoylation, or addition of
16-carbon saturated fatty acid, palmitic acid to the receptors is a part of post-translational
modifications of GPCRs (Chini and Parenti, 2009). Although the palmitoylation can
exist in intracellular loops of the GPCRs, it is most common at the C-terminal (Qanbar
and Bouvier, 2003).

76

Addition of the palmitate could have many functions in a receptor. It can be
involved in plasma membrane localization of the receptor. Blocking the palmitoylation
reduced the number of receptors reaching the cell surface in TSH receptor, δ-opioid
receptor and histamine H2 receptor (Tanaka et al., 1998; Fukushima et al., 2001; PetajaRepo et al., 2006). Palmitoylation can be involved in receptor-G-protein coupling
(O'Dowd et al., 1989b). In the muscarinic acetylcholine receptor M2, the lack of
palmitoylation reduced the ability of G proteins to activate (Hayashi and Haga, 1997). In
human somatostatin receptor type 5, the mutation of the palmitoylation sites led to a
reduced coupling to adenylate cyclase (Hukovic et al., 1998). The effects of
palmitoylation on signaling are not universal. Human A1 adenosine receptor and
dopamine D1 receptor are some of the receptors where the signaling is not affected by
lack of palmitoylation (Jin et al., 1997; Gao et al., 1999). The C-terminal tails of the MT1
and MT2 receptors contain a single cysteine residue, which could be a possible
palmitoylation site and may form a fourth intracellular loop. Mutation of this cysteine
within the melatonin receptors might prevent the fourth intracellular loop from forming,
which may affect receptor function.
In the second mutation, the C-terminal tail in the MT1 and MT2 receptors was
truncated (MT1Y7.64 and MT2Y7.64). The role of the C-terminal tail in receptor
phosphorylation and subsequent beta-arrestin binding is well-known. Beta-arrestins are
proteins that are involved in the desensitization of most GPCRs (DeWire et al., 2007) ,
including MT1 (Bondi et al., 2007) and MT2 receptors (Gerdin et al., 2003a). In most
GPCRs, upon prolonged agonist stimulation, GPCRs undergo conformational changes
that are recognized by the family of GPCR kinases (GRKs) that phosphorylate the serine,
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threonine, and tyrosine residues on their intracellular loops and C-terminal tails (Premont
and Gainetdinov, 2007; Kovacs et al., 2009). Beta-arrestin recruitment to these
phosphorylated amino acids stearically blocks the binding of the receptor to G proteins,
thus causing acessation of G protein signaling (desensitization), despite the continued
presence of the receptor-activating agonist. The arrestins form a complex which is
transferred to clathrin coated pits for endocytosis, recycling and degradation (DeWire et
al., 2007). Based on this information, it was hypothesized that truncation of the Cterminal tail of the melatonin receptors would remove a majority of these
phosphorylation sites and impair receptor internalization.
The mutations were named according to the scheme described by Ballesteros and
Weinstein. The most conserved residue within each transmembrane domain was
designated number 50 (in this case alanine) and is preceded by the number of the TM
domain (Ballesteros J and Weinstein., 1995).
Because it has been shown that desensitization/ internalization processes drive
cellular events induced by melatonin (Radio et al., 2006; Bondi. et al., 2007) and betaarrestin scaffolds modulate melatonin receptor function (Gerdin et al., 2003a; Bondi. et
al., 2007), the focus of this study was to determine if the above mentioned domains were
involved in melatonin receptor desensitization and internalization processes.
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7. MATERIALS AND METHODS
7.1

Cell Culture and Transfections
COS-7 cells were grown as monolayers in Dulbecco's modified Eagle's medium

containing 10% fetal bovine serum (FBS) and 2 mM glutamine. The cells were grown to
60–70% confluence and transiently transfected with MT1 or MT2 wild-type (WT) or
mutant constructs using genePORTER transfection reagent (Genlantis, San Diego, CA),
as per manufacturer's instructions.
7.2

Construction of Mutant Plasmids
Two mutations were made to the genes encoding human MT1 or MT2 receptors

(Fig. 18) using site-directed mutagenesis (Quikchange ll; Stratagene, La Jolla, CA),
according to manufacturer's instructions. In the first mutation, a cysteine residue in the
C-terminal tail of each receptor was converted to alanine using primer pairs
(MT1C7.72A: forward = GAATTATAGTCTCGC TCGCTACAGCCAGGGTGTTC;
reverse = GAACACCCTGGCTGTAGCGAGCGAGACTATAATTC) and (MT2C7.77A:
forward = GAACCCACGGCACGCCATTCAAGATGCTTC;
reverse = GAAGCATCTTGAATGGCGTGCCGTGGGTTC). This substitution removes
the putative palmitoylation site of the C-terminal tail, an important component for
signaling in some other GPCRs. In the second mutation, the C-terminal tail of each
receptor was truncated, deleting all potential phosphorylation sites in the C-terminal tail
using primer pairs (MT1Y7.64:
forward = CCAAAATTTCAGGAAGGAATAAAGGAGAATTATAGTCTCGCTC;
reverse = GAGCGAGACTATAATTCTCCTTTATTCCTTCCTGAAATTTTGG) and
(MT2Y7.64: forward = CCAAAACTTCCGCAGGGAATAAAAGAGGATCCTCTTG;
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reverse = CAAGAGGATCCTCTTTTATTCCCTGCGGAAGTTTTGG). All constructs
included a green fluorescent protein (GFP) tag at the C-terminal region. Gene products
for MT1 WT, MT2 WT, MT1Y7.64 and MT2Y7.64 were each cloned into pcDNA3
(Invitrogen), and the gene products for MT1C7.72A and MT2C7.77A were each cloned
into pcDNA1 (Invitrogen, Carlsbad, California). All mutants were confirmed by
sequencing.
7.3

Radioligand Binding Assays
Saturation binding assays were performed using 2-[125I]-iodomelatonin on whole

cell lysates. The COS-7 cells were grown and transfected with the MT1 or MT2 WT or
mutant constructs in 10-cm2 culture dishes, as described in the methods section. On the
third day after transfection, cells were washed twice with 2 mL of phosphate-buffered
saline (PBS) and collected in buffer (0.25 M sucrose, 10 mM potassium phosphate, 1 mM
EDTA, pH 7.4) and pelleted by centrifugation (500 x g, 5 min). The cells were then
resuspended in cold Tris-HCl (50 nM, pH 7.4) buffer containing 1 X complete mini
protease inhibitors (Roche Diagnostics, Mannheim, Germany), and aliquoted into tubes
containing concentrations of 2-[125I]-iodomelatonin (2,200 Ci/mmole; NEN/DuPont,
Boston, MA) ranging from 0-1 nM in the absence or presence of 1 M melatonin. The
reactions were incubated for 1 h at room temperature and then terminated by ice-cold
Tris-HCl buffer (50 nM, pH 7.4). Filtration was performed using glass fiber filters (0.22
μM), presoaked in 0.5% polyethylinimine, and using a Brandel Cell Harvester. Each
filter was washed twice with 5 ml Tris-HCl buffer. Radioactivity was counted using a
gamma counter. Saturation analysis was performed using GraphPad Prism Software
(GraphPad Inc., San Diego, CA). The affinity (KD) and density (Bmax) of 2-[125I]-
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iodomelatonin binding were determined for each experiment performed and then
averaged. Statistics were performed using one-way ANOVA followed by a NewmanKeuls post hoc t-test where significance was set at p<0.05.
7.4

cAMP Accumulation Assays
The cAMP accumulation assays were carried out by enzyme immuno-antibody

according to manufacturer's instructions. COS-7 cells were transfected with MT1 or MT2
WT or mutant constructs in 12-well plates. On the third day after transfection, the cell
medium was aspirated, and the cells were incubated in serum-free media containing
either 30 μM rolipram alone (basal), 30 μM rolipram and 100 μM forskolin (maximal
accumulation) or 30 μM rolipram, 100 μM forskolin and 10 nM melatonin. cAMP
accumulation was expressed as a percentage of forskolin response within each group.
Statistical analysis was performed using commercial software (graphpad prism®,
GraphPad Prism, Inc.), whereby the maximal efficacy of melatonin to inhibit forskolininduced cAMP accumulation was compared against the maximal forskolin response
within each group.
7.5

Confocal Microscopy
The cells were grown and transfected with MT1 or MT2 WT or mutant constructs,

as described in the methods section. On the third day after transfection, the cells were
lifted with trypsin and seeded on sterile coverslips for 24 h in 6-well plates. Cells were
incubated in serum-free media for 5 h at 37°C and incubated with 1 μM melatonin or
vehicle (0.001% ethanol) for 1 h. The cells were then washed twice with PBS and fixed
with 2% paraformaldehyde for 15 min. Coverslips were mounted on slides and then
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visualized under oil immersion at 1000× using a Leica TCS-SP2 confocal laser
microscope (Leica Microsystems, Inc., Confocal Division, Exton, PA).
7.6

Radiolabeling with [3H] Palmitic Acid
Radiolabeling of MT1 WT and MT2 WT receptors with [3H] palmitic acid was

carried out as previously described (Das et al., 2007). COS-7 cells were grown in sixwell plates until the cells reached 60–80% confluence. Cells were then transfected with
the MT1 or MT2 WT constructs. Twenty-four hours after transfection, cells were labeled
with 50 μCi/mL 9,10-[3H] palmitic acid for 16 h in the same media with reduced serum
(3% FBS). Cells were then washed once with PBS, and scraped in cold RIPA buffer
(Boston Bioproducts, Worcester, MA). Aliquots of cell lysate were added to scintillation
vials and counted in a liquid scintillation counter or used in a cell proliferation assay.
The amount of [3H] palmitic acid counts were expressed as fmol/total cell count. Cell
proliferation assay was performed on the scraped cells using one solution cell
proliferation assay kit (Promega, Madison, WI) as per manufacturer's instructions.
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Figure 18: Details of the C-terminal Mutations
(A) Diagram representing the site of the C-terminal mutations in MT1 and MT2 melatonin
receptors. (B) Amino acid sequence of the C-terminal tails of the MT1WT and MT2 WT
receptors. In mutants MT1Y7.64 and MT2Y7.64, all the above amino acids were removed
in their respective receptor type to remove the putative phosphorylation sites in the C-tail
(the amino acids represented in bold). In mutants MT1C7.72A and MT2C7.77A, a
cysteine residue in the respective C-tails was mutated to alanine (the underlined cysteines
in the above sequence).

83

8. RESULTS
8.1

Effect of the C-terminal mutations on Affinity and Density of 2-[125I]Iodomelatonin Binding to MT1 and MT2 Melatonin Receptors Expressed in
COS-7 cells
To determine if the mutations in the MT1 and MT2 receptors caused any changes

in their affinity and density compared to WT receptors, saturation binding was carried out
on COS-7 cells transfected with the various constructs. The results revealed that the
affinity and density of 2-[125I]-iodomelatonin for the mutant receptors was similar to the
affinity and density obtained for WT type receptors (Table 2).

Receptor

KD (pM)

Bmax (fmol/mg protein)

MT1WT

80 ± 20

0.5 ± 0.2

MT1Y7.64

76 ± 16

0.5 ± 0.1

MT1C7.72A

60 ± 23

14 ± 11

MT2WT

73 ± 8

0.9 ± 0.4

MT2Y7.64

56 ± 8

0.3 ± 0

MT2C7.77A

75 ± 38

0.7 ± 0.2

Table 1: Saturation Binding Analysis of 2-[125I]-Iodomelatonin Binding to Mutant
and MT1 WT and MT2 WT Receptors
Saturation binding was performed on whole cell lysates of COS-7 cells transiently
expressing MT1 WT and MT2 WT receptors as well as their respective mutants. The
affinity (KD) or Bmax values for 2-[125I]-iodomelatonin binding were not significantly
different between WT and mutant receptors. The data was analyzed by one-way ANOVA
followed by Newman-Keul‟s post hoc t- test. Each value represents the mean ± SEM of
3-5 independent experiments.
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8.2

Effect of C-terminal Mutations on Melatonin-Mediated Inhibition of
Forskolin-Induced cAMP Accumulation in Naive COS-7 cells Expressing MT1
and MT2 Receptors
To determine if the mutations affected melatonin-mediated decreases in forskolin-

induced cAMP accumulation, cAMP assays were carried out in naive cells (i.e.,. cells
never exposed to melatonin). As shown in Fig. 19, melatonin (10 nM) inhibited
forskolin-induced cAMP accumulation in COS-7 cells expressing the WT melatonin
receptors. However, no inhibition of forskolin-induced cAMP accumulation by melatonin
(10 nM) occurred in COS-7 cells expressing either of the MT1 or of the MT2 receptor
mutants.
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Figure 19: Melatonin Mediated Inhibition of Forskolin-induced cAMP
Accumulation in COS-7 cells Transiently Expressing WT or Mutant Melatonin
Receptors
As shown, a 20 min exposure to 10 nM melatonin inhibited forskolin-induced cAMP
accumulation when compared to the forskolin response alone. By contrast, expression of
mutant MT1 (MT1C7.72A, MT1Y7.64) or MT2 (MT2C7.77A, MT2Y7.64) receptors
within COS-7 cells followed by a 20 min exposure to melatonin did not result in an
inhibition of cAMP accumulation induced by 100 μM forskolin. Each bar graph
represents the mean ± SEM of 6-8 individual experiments performed in duplicate. The
data was analyzed by one-way ANOVA followed by Newman-Keul‟s post hoc t- test.
Significance (*) is defined as p < 0.05 when compared to the forskolin response alone.
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8.3

Effect of the C-terminal Mutations on Melatonin-Mediated Inhibition of
Forskolin-Induced cAMP Accumulation in COS-7 cells Expressing MT1 and
MT2 Receptors that were Pretreated with 1 µM Melatonin
To determine if the C-terminal mutations affected the desensitization patterns of

MT1 and MT2 receptors, COS-7 cells expressing either the WT or mutant forms of the
receptors were first pretreated with 1 µM melatonin for 1 h, washed and then
rechallenged with 10 nM melatonin for 20 min. It was expected that MT1 WT, but not
the MT2 WT receptors would be resistant to desensitization as shown by previous studies
(Witt-Enderby and Dubocovich, 1996; Witt-Enderby et al., 2003). It was expected that
the mutations could alter the sensitivity state of MT1 WT receptors by making them more
prone to desensitization. Results show that pretreatment with melatonin desensitized
MT2 WT receptors reflected by attenuation in melatonin-induced inhibition of forskolininduced cAMP accumulation. The selected mutations within the MT2 receptors were
without effect (Fig. 20). As for the MT1 WT receptors, a 1 h pretreatment with melatonin
did not desensitize the receptor reflected by no attenuation in melatonin-mediated
inhibition of forskolin-induced cAMP accumulation. The C-terminal mutations were
without effect on modifying the responses of the MT1 or MT2 receptors to this melatonin
exposure.
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Figure 20: Melatonin Mediated Inhibition of Forskolin Induced cAMP
Accumulation in Melatonin-Pretreated COS-7 cells Transiently Expressing WT or
Mutant Melatonin Receptors
As shown, a rechallenge with 10 nM melatonin inhibited forskolin-induced cAMP
accumulation in COS-7 cells expressing the wild type MT1 receptor (MT1 WT) even after
a 1h prior exposure to melatonin. By contrast, no melatonin-mediated inhibition of
forskolin-induced cAMP accumulation occurred in COS-7 cells expressing wild type
MT2 receptors (MT2 WT). The C-terminal mutations for each of the melatonin receptor
subtypes, MT1 (MT1C7.72A, MT1Y7.64) or MT2 (MT2Y7.64 and MT2C7.77A), were
without effect when compared to WT receptors exposed to the same melatonin
pretreatment. Each bar graph represents the mean ± SEM of 3-5 individual experiments
performed in duplicate. The data was analyzed by one-way ANOVA followed by
Newman-Keul‟s post hoc t- test. Significance (*) is defined as p < 0.05 when compared
to forskolin response alone within each group.
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8.4

Effect of the C-terminal Mutations on the Internalization Patterns of MT1 and
MT2 Receptors Expressed in COS-7 Cells following Melatonin Exposure
All mutants and WT constructs used in this study were tagged with GFP, enabling

visualization of the receptors through confocal microscopy to determine the location of
the receptors in a cell. As shown in Fig. 21, the WT MT1 and MT2 receptors internalized
following melatonin pretreatment, depicted by a punctate and cytosolic distribution of the
GFP-tagged receptor (panels B and H) when compared with their vehicle controls (panels
A and G). The cysteine mutants (MT1C7.72A and MT2C7.77A) also internalized in
response to melatonin (panels D and J) when compared with their controls (panels C and
I) similar to the WT receptors, indicating the lone cysteine residue in the C-terminal tails
of these receptors did not play a role in receptor internalization. The truncation mutants
(MT1Y7.64 and MT2Y7.64) did not internalize after melatonin treatment (panels F and L)
when compared with their control cells treated with vehicle (E and K). The location of
the GFP-tagged receptors remained at the plasma membrane even after melatonin
exposure, suggesting that the C-terminal tail is essential for melatonin receptor
internalization.
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Figure 21: Internalization Patterns of Green Fluorescent Protein-Tagged WT and
Mutant Receptors Following Exposure to Melatonin
As shown, a 1 h exposure to 1 μM melatonin (B and H) induced internalization of wildtype MT1 and MT2 receptors expressed in COS-7 cells when compared with vehicle
controls (A and G). Mutation of the cysteine residue in each of the melatonin receptor
subtypes, MT1 (MT1C7.72A) and MT2 (MT2C7.77A) receptors internalized in response
to melatonin (D and J) similar to wild type (C and I). However, truncation of the Cterminal tail in each of the receptor subtypes, MT1 (MT1Y7.64) and MT2 (MT2Y7.64)
prevented this internalization response to melatonin (F and I) when compared with their
vehicle controls (E and K). Images are representative of six to seven independent
experiments. Cells were visualized under oil immersion using a 100X-400X objective.
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8.5

Effect of Palmitoylation on MT1 WT and MT2 WT Receptors.
To determine if the MT1 WT and MT2 WT melatonin receptors were

palmitoylated COS cells transiently transfected with MT1 WT and MT2 WT melatonin
receptors, were labeled in culture with 9,10-[3H] palmitic acid for 16 h, and the
incorporated radioactivity was measured. Palmitoylation at the C-terminal tail is thought
to embed the tail in the cellular membrane, forming a 4th intracellular loop. As shown in
Fig. 22, MT1 WT, but not MT2 WT receptors, incorporated significantly higher levels of
[3H] palmitic acid when compared with un-transfected COS-7 cells.
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Figure 22: Incorporation of 9, 10-[3H] palmitic acid in COS-7 Cells Transiently
Transfected with MT1 WT and MT2 WT Receptors
The incorporation of [3H] palmitic acid was significantly increased in MT1WT constructs
as compared to untransfected cells. Each bar graph represents the mean ± SEM of 3-4
individual experiments. The data was analyzed by one-way ANOVA followed by
Newman-Keul‟s post hoc t- test. Significance (*) is defined as P < 0.05 when compared
to untransfected cells.
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9. DISCUSSION
The results from this study demonstrate the importance of the C-terminal domains
within each of the MT1 and MT2 melatonin receptors as it relates to modulating receptor
function and desensitization responses.
Essential to the study of receptor regulation using mutagenesis approaches is the
requirement that the mutations do not affect the binding affinity of the agonist to its
receptor. If the binding of the agonist to the receptor were to be affected because of the
mutations, it would not be possible to determine if any change in receptor function was
because of the change in binding or because of the mutations. As revealed through
saturation binding analysis using the agonist radioligand, 2-[125I]-iodomelatonin, there
were no significant changes in the affinity (KD) of 2-[125I]-iodomelatonin for these
mutated receptors compared to their respective WT receptors (Table 2) or to those values
reported in the literature (Ekmekcioglu, 2006). It was expected that mutation of the Cterminal tails of each of the melatonin receptor subtypes would not affect agonist binding
affinity because the ligand binding site for melatonin receptors is thought to lie between
TM 5-7 (Navajas et al., 1996; Barrett et al., 2003), and TM 3 (Navajas et al., 1996;
Kokkola et al., 2003) for MT1 receptors and TM 4-5 for MT2 receptors (Barrett et al.,
2003; Gerdin et al., 2003b).
In the first type of mutation, the cysteine residue in the C-terminal tail of each
receptor was mutated to alanine (MT1C7.72A and MT2C7.77A), which does not contain
the thiol groups capable of being palmitoylated, and therefore, was an ideal choice for the
mutation. This cysteine is a palmitoylation site in many other GPCRs, and serves to form
a fourth intracellular loop by embedding the palmitoyl groups into the membrane. This
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loop is important in G-protein binding and activation of the rhodopsin receptor (Ernst et
al., 2000), and the absence of this loop in some receptors has led to G protein uncoupling
(O'Dowd et al., 1989a; Hayashi and Haga, 1997). In this study, mutation of the cysteine
residue within the C-terminal domain of each of the melatonin receptor subtypes, MT1
and MT2 (MT1C7.72A and MT2C7.77A), blocked the transfer of signal from the receptor
to inhibit cAMP production. The absence of this potential palmitoylation site within each
of the melatonin receptor subtypes possibly disrupts the formation of the fourth
intracellular loop; a loop that may bind directly to Gi-proteins. This disruption in
receptor/ Gi-protein coupling may result in attenuated cAMP inhibitory responses coming
from their respective receptors.
Uncoupling of melatonin receptors from Gi proteins using either GTPγS or
pertussis toxin results in attenuated cAMP inhibitory responses in CHO cells (WittEnderby and Dubocovich, 1996). Though not tested in this study, it is also possible that
the cysteine mutations make the melatonin receptors more prone to desensitization by
somehow allowing easier access of G-protein receptor kinases to these phosphorylation
sites. This hypothesis of heightened sensitization is speculative and more studies are
required to support this idea. Similar results have been reported for β2-adrenergic
receptor, where in addition to being uncoupled from Gα, a palmitoylation mutant
(Cys341Gly) was hyperphosphorylated (Moffett et al., 1993). Although there may be
additional residues in the C-terminal tail in addition to these cysteine residues, which are
required for downstream cAMP signaling of the MT1 and MT2 receptors, taken together,
the findings from both C-terminal mutations suggest that cysteine 7.72 in MT1 receptors
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and 7.77 in MT2 receptors plays an important role in transducing cAMP responses
throughout the cell.
Desensitization is a process in which a receptor becomes refractory to its agonist
over time. Many reports have shown that melatonin receptors become desensitized
following exposure to melatonin either directly (Gerdin et al., 2003a; Jarzynka MJ et al.,
2006; Bondi et al., 2007) or during the night when melatonin levels are highest (Gauer et
al., 1994). In this study, MT2 WT receptors but not MT1 receptors desensitized after a 1h
pretreatment with 1 µM melatonin. These data are consistent with previous studies
(Witt-Enderby and Dubocovich, 1996; Witt-Enderby et al., 2003). In this study, neither
of the C-terminal mutations altered the responses of each of the receptor subtypes (MT1,
MT2) to a 1h exposure to 1 µM melatonin. These data suggest that the lack of signal
transfer through each of the melatonin receptors due to the cysteine 7.72 (MT1) or 7.77
(MT2) mutation prevented these receptor mutants from responding to the melatonin
exposure like their WT counterparts.
Besides desensitizing through uncoupling, melatonin receptors, in response to
agonist exposure, also desensitize by internalization of the receptors (Gerdin et al.,
2003a; Gerdin et al., 2003b; Bondi et al., 2007). As revealed through the internalization
assays, truncation of the C-tail of each of the melatonin receptor subtypes (MT1Y7.64 or
MT2Y7.64) prevented melatonin-induced internalization of MT1 and MT2 receptors when
compared to their WT counterparts. By contrast, the cysteine point mutations at position
7.72 for MT1 receptors or position 7.77 for MT2 receptors displayed internalization
patterns similar to what was observed for their WT receptors. As described earlier,
blocking the palmitoylation reduced the number of receptors reaching the cell surface in
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TSH receptors, δ-opioid receptors and histamine H2 receptors (Tanaka et al., 1998;
Fukushima et al., 2001; Petaja-Repo et al., 2006). The internalization data from the
cysteine mutations show that unlike these receptors, the cysteine mutated receptors were
able to traffic normally to the cell surface, similar to the WT receptors. These data
suggest that these amino acids are not involved in melatonin-induced internalization
processes.
Overall, the findings from the internalization assays show that the C-terminal tails
within the MT1 and MT2 WT receptors function in melatonin receptor internalization. As
such, removal of these sites through truncation mutagenesis prevented melatonin-induced
internalization responses. Because these C-terminal tails contain many putative
phosphorylation sites, these tails may modulate melatonin receptor internalization by
providing the binding site to which beta-arrestins can bind similar to what occurs for
other GPCRs (Ferguson, 2001).
Palmitoylation assays demonstrate that the MT1 WT receptors are palmitoylated
when compared to non-transfected COS-7 cells. The palmitoylation of MT2 WT
receptors was not significantly different than untransfected cells, which may suggest that
palmitoylation occurs in MT1 receptors (perhaps in the C-tail) but not in MT2 receptors.
Even though no significant difference in [3H] palmitate incorporation occurred in MT2
receptors, this could be due to a limitation to the assay conditions (i.e., transiently
transfected cells). More experiments need to be performed in this area to support or
refute this idea.
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10. CONCLUSION
This study reveals many important findings regarding those domains within the
melatonin receptor that underlie desensitization processes. Considering that
desensitization events may underlie melatonin-induced cellular differentiation (Radio et
al., 2006; Bondi et al., 2007), then understanding the role that specific domains play in
melatonin receptor function may lead to novel melatonin therapies targeted to enhance
cellular differentiation such as for the treatment of cancer and osteoporosis (WittEnderby et al., 2006). Additionally, the knowledge gained from this study could lead to
novel therapeutic targets as it relates to melatonin and melatonin-related disorders
including insomnia and depression.
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12. APPENDIX
12.1 Sample Calculations for measuring ALP Activity in hAMSCs

well 1

well 2

average average- blank

405 nM 405 nM
blank 0.048

0.054

0.051

0

0

0.075

0.077

0.076

0.025

12.5

0.196

0.169

0.182

0.131

25

0.329

0.322

0.326

0.275

37.5

0.459

0.45

0.459

0.408

50

0.572

0.561

0.567

0.516

62.5

0.673

0.696

0.685

0.634

75

0.78

0.837

0.813

0.762

Table 2: Standard Curve Values Depicting the Rate of Hydrolysis of p-Nitrophenyl
Phosphate Disodium Hexahydrate

Standard curve depicting rate of hydrolysis of p-nitrophenyl
phosphate disodium hexahydrate
y = 0.0099x + 0.0231
Absorbance at 405nM

R2 = 0.9988
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Figure 23: Standard Curve Depicting the Rate of Hydrolysis of p-Nitrophenyl
Phosphate Disodium Hexahydrate
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µg protein well 1

well 2

well 3

average average-blank

405 nM 405 nM 405 nM
blank

0.105

0.109

0.107

0.107

0.000

0

0.117

0.117

0.108

0.114

0.014

5

0.127

0.126

0.127

0.127

0.027

10

0.142

0.133

0.128

0.134

0.034

20

0.151

0.145

0.141

0.146

0.046

30

0.156

0.152

0.139

0.149

0.049

40

0.170

0.166

0.167

0.168

0.068

50

0.181

0.191

0.186

0.186

0.086

60

0.199

0.199

0.204

0.201

0.101

100

0.236

0.234

0.223

0.231

0.131

200

0.333

0.338

0.355

0.342

0.242

Table 3: Standard Curve Values Depicting Total Protein via BSA Assay

Total protein standard curve for ALP activity
y = 0.0011x + 0.0222
R2 = 0.992

Absorbance at 405nM

0.3
0.25
0.2
0.15
0.1
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0
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50
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150

200

Total protein (µg)

Figure 24: Standard Curve Depicting Total Protein
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12.2 Sample Calculations for Quantitative Analysis of Osteogenesis
µM

well 1

well 2

well 3

average

average blank

blank

0.045

0.045

0.046

0.045

0.000

2000.00 1.646

1.691

1.663

1.667

1.622

1000.00 0.894

0.889

0.887

0.890

0.845

500.00

0.489

0.485

0.493

0.489

0.444

250.00

0.278

0.284

0.287

0.283

0.238

125.00

0.161

0.176

0.171

0.169

0.124

62.50

0.107

0.113

0.108

0.109

0.064

31.30

0.080

0.078

0.078

0.079

0.034

15.00

0.076

0.078

0.077

0.077

0.032

7.50

0.061

0.061

0.061

0.061

0.016

3.75

0.053

0.053

0.054

0.053

0.008

1.88

0.049

0.051

0.048

0.050

0.005

0.94

0.047

0.049

0.046

0.047

0.002

Table 6: Standard Curve Values Depicting Colorimetric Analysis of Known
Concentrations of Alizarin Red Solutions
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Absorbance at 405nM

Standard curve for osteogenesis quantitation
y = 0.0008x
R2 = 0.9981

1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
0

500

1000

1500

2000

2500

alizarin red concentration(µM)

Figure 25: Standard Curve Depicting Colorimetric Analysis of Known
Concentrations of Alizarin Red Solutions

well 1

well 2

well 3

405

405

405

nM

nM

nM

average average blank

quantitation %
of samples

control

using Fig.
26

control 0.143

0.141

0.121

0.135

0.090

112.500

100.000

21d

0.887

0.923

0.913

0.868

1084.417

963.926

0.928

Table 7: Sample Calculation for Quantitative Analysis of Osteogenesis of Control
vs. 21 d Melatonin Exposure
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12.3 Sample Calculations for Real- Time RT- PCR
Real-time PCR results were analyzed using the ΔΔCt method as described by
Livak & Schmittgen (2001). The step by step representation of this method is given
below.
1. Calculation of Ct value: Ct values represent the cycle number. The Ct values were
calculated from the PCR graph by extrapolating the threshold value (set at 100) to X axis
(see representative graph in Fig. 27).
1400
1300

PCR Baseline Subtracted RFU

1200
1100
1000
900
800
700
600
500
400
300
200
100
0
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16

20

24

28
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40

44

48

52

Cycle number
GAPDH
Control
Ct = 16

GAPDH
21 d mel
Ct = 20

Gene of
interest

Gene of
interest

Control

21 d mel

Ct = 34

Ct = 40

Figure 26: Sample Real-time PCR Graph Depicting Ct values for GAPDH and
Gene of Interest
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2. Determination of threshold value: The threshold value was set at a value above the
background fluorescence but within the linear phase. Fig. 28 illustrates the
logarithmic graph view of the PCR data. The fluorescence threshold value was set at 100
RFU.

Figure 27: Logarithmic Graph View of Example Real-Time PCR data
The fluorescence threshold value was set at 100 RFU.

3. Calculation of fold change in gene expression over control: The ΔCt values were
calculated by subtracting the Ct value of the housekeeping gene (GAPDH) from the Ct
value of the gene of interest. A lower Ct value indicates higher gene expression. The ΔCt
values in each group were averaged and used to calculate the relative fold change in
expression (2-ΔΔCt).
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Gene of
interest
Ct

GAPDH
Ct

∆ Ct
(gene of
interestGAPDH)

(∆ ∆ Ct)
(treatment
– control)

2-(∆ ∆ Ct)
Fold
change

control

34

16

18

0

1

21d mel

40

20

20

2

0.25

Table 8: Calculation of Fold Change in Gene Expression with 21 d Melatonin
Exposure over Control
4. Melt curve analysis: A melt curve analysis was performed after the real-time PCR
runs. A melt curve detects the melting temperature of the product in the reaction well.
Each PCR product has a specific melting temperature and a single melt peak indicates the
presence of a single product.

Figure 28: Sample Real-Time PCR Melt Curve
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